STERIS (STE) 10-K 26 May 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2023	May 23, 2023	Sep. 30, 2022
Entity Information [Line Items]
Document Annual Report	true
Document Transition Report	false
Entity Central Index Key	0001757898
Document Period End Date	Mar. 31, 2023
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
ICFR Auditor Attestation Flag	true
Local Phone Number	232 2000
City Area Code	1
Country Region	353
Entity Shell Company	false
Entity Registrant Name	STERIS plc
Document Type	10-K
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Entity Public Float			$ 16,561,000,000
Entity Common Stock, Shares Outstanding		98,650,238
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Ordinary Shares
Entity Information [Line Items]
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Mar. 31, 2023
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Cleveland, Ohio

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Jun. 02, 2021
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 23,427	$ 24,371
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001
Common Stock, Shares Authorized	500,000
Common shares issued	98,629	100,067
Common shares outstanding	98,629	100,067

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 208,357	$ 348,320
Accounts receivable (net of allowances of $23,427 and $24.371, respectively)	928,315	799,041
Inventories, net	695,493	574,999
Prepaid expenses and other current assets	179,277	156,637
Total current assets	2,011,442	1,878,997
Property, plant, and equipment, net	1,705,512	1,552,576
Operating Lease, Right-of-Use Asset	191,741	188,480
Goodwill	3,879,219	4,404,343
Intangible Assets, Net (Excluding Goodwill)	2,955,780	3,328,537
Other assets	78,145	70,661
Assets	10,821,839	11,423,594
Current liabilities:
Accounts payable	279,620	225,737
Accrued Income Taxes, Current	43,804	26,873
Accrued payroll and other related liabilities	125,642	183,721
Capital Lease Obligations, Current	34,961	36,472
Accrued expenses and other	317,817	306,544
Short-term Debt	60,000	142,875
Total current liabilities	861,844	922,222
Long-term indebtedness	3,018,655	2,945,481
Deferred income taxes, net	617,538	780,619
Capital Lease Obligations, Noncurrent	160,493	155,056
Other Liabilities, Noncurrent	76,137	75,579
Total liabilities	4,734,667	4,878,957
Commitments and contingencies (see note 10)
Ordinary shares, with $0.001 par value; 500,000 shares authorized; 98,629 and 100,067 ordinary shares issued and outstanding, respectively	4,486,375	4,742,920
Retained earnings	1,911,533	1,999,244
Accumulated other comprehensive income	(320,710)	(209,808)
Total shareholders' equity	6,077,198	6,532,356
Noncontrolling interest	9,974	12,281
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,087,172	6,544,637
Total liabilities and equity	$ 10,821,839	$ 11,423,594

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total revenues		$ 4,957,839	$ 4,585,064	$ 3,107,519
Cost of revenues:
Cost of Goods and Services Sold		2,798,147	2,568,702	1,764,419
Gross Profit		2,159,692	2,016,362	1,343,100
Operating expenses:
Selling, general, and administrative		1,298,876	1,502,752	731,320
Goodwill, Impairment Loss	[1]	490,565	0	0
Research and development		101,581	87,944	66,326
Restructuring Costs		485	48	(2,914)
Total operating expenses		1,891,507	1,590,744	794,732
Income (loss) from operations		268,185	425,618	548,368
Non-operating expenses, net:
Interest expense		107,989	89,593	37,180
Fair value adjustment related to convertible debt liability		0	27,806	0
Interest income and miscellaneous expense		2,848	(6,284)	(6,345)
Total non-operating expenses, net		110,837	111,115	30,835
Income (loss) before income tax expense (benefit)		157,348	314,503	517,533
Income tax expense (benefit)		51,535	71,633	120,663
Net income		105,813	242,870	396,870
Less: Net loss attributable to noncontrolling interests		(1,217)	(1,018)	(530)
Net income attributable to shareholders		$ 107,030	$ 243,888	$ 397,400
Net income (loss) per common share
Basic		$ 1.07	$ 2.50	$ 4.66
Diluted		1.07	2.48	4.63
Cash dividends declared per common share outstanding		$ 1.84	$ 1.69	$ 1.57
Product [Member]
Revenues:
Total revenues		$ 2,785,327	$ 2,556,281	$ 1,443,540
Cost of revenues:
Cost of Goods and Services Sold		1,513,970	1,419,925	765,076
Service [Member]
Revenues:
Total revenues		2,172,512	2,028,783	1,663,979
Cost of revenues:
Cost of Goods and Services Sold		$ 1,284,177	$ 1,148,777	$ 999,343
[1]For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Consolidated Statements of Comprehensive Income [Abstract]
Net income	$ 105,813	$ 242,870	$ 396,870
Less: Net loss attributable to noncontrolling interests	(1,217)	(1,018)	(530)
Net income attributable to shareholders	107,030	243,888	397,400
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax	(1,264)	6,795	1,294
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(109,638)	(155,360)	172,926
Total other comprehensive (loss) income attributable to shareholders	(110,902)	(148,565)	174,220
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (3,872)	$ 95,323	$ 571,620

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	$ 521	$ 507	$ 667

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022		Mar. 31, 2021
Statement of Cash Flows [Abstract]
Net income		$ 105,813	$ 242,870		$ 396,870
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization		552,897	553,104	[1]	219,237
Deferred income taxes		(185,913)	(106,620)		4,240
Share-based compensation		38,951	57,660		25,966
Loss on the disposal of property, plant, equipment, and intangibles, net		22,193	15,117		(1,982)
Loss (Gain) on Disposition of Business	[2]	(67)	(874)		2,030
Fair value adjustment related to convertible debt liability		0	27,806		0
Amortization of inventory fair value adjustments		7,363	66,663		0
Goodwill, Impairment Loss	[3]	490,565	0		0
Other items		(24,832)	(21,639)		24,273
Changes in operating assets and liabilities:
Accounts receivable, net		(133,304)	(51,969)		12,076
Inventories, net		(123,921)	(102,922)		3,769
Other current assets		(24,086)	7,126		458
Accounts payable		53,342	14,887		(7,213)
Accruals and other, net		(22,054)	(16,398)		9,916
Net cash provided by operating activities		756,947	684,811		689,640
Investing activities:
Purchases of property, plant, equipment, and intangibles, net		(361,969)	(287,563)		(239,262)
Proceeds from the sale of property, plant, equipment, and intangibles		14,587	1,741		569
Proceeds from Divestiture of Businesses		6,624	169,712		518
Payments to Acquire Investments		0	0		(4,400)
Investments in businesses, net of cash acquired		(42,572)	(550,449)		(909,192)
Payments for (Proceeds from) Other Investing Activities		0	0		(2,392)
Net cash used in investing activities		(383,330)	(666,559)		(1,154,159)
Financing activities:
Proceeds from Issuance of Senior Long-term Debt		0	1,350,000		0
Proceeds from Issuance of Debt		0	650,000		550,000
Repayments of Secured Debt		(156,875)	(345,000)		0
Repayments of Long-term Debt		(91,000)	(721,284)		(35,000)
Repayments of Convertible Debt		0	(371,361)		0
Proceeds Under Credit Facility, net		241,657	(190,174)		(30,461)
Amortization of Financing Costs		0	(17,472)		(12,846)
Payments of Merger Related Costs, Financing Activities		(1,471)	(32,679)		(2,395)
Repurchases of ordinary shares		(308,565)	(55,777)		(14,646)
Cash dividends paid to common shareholders		(183,498)	(163,169)		(133,837)
Payments to Noncontrolling Interests		(794)	(997)		(4,179)
Proceeds from Noncontrolling Interests		0	3,672		2,258
Proceeds from (Payments for) Other Financing Activities		1,828	10,071		26,726
Net cash (used in) provided by financing activities		(498,718)	115,830		345,620
Effect of exchange rate changes on cash and cash equivalents		(14,862)	(6,293)		19,849
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect		(139,963)	127,789		(99,050)
Cash and cash equivalents at beginning of period		348,320	220,531		319,581
Cash and cash equivalents at end of period		$ 208,357	$ 348,320		$ 220,531
[1]Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."[2]For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."[3]For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Previously Reported	Ordinary Shares	Ordinary Shares Previously Reported	Retained Earnings [Member]	Retained Earnings [Member] Previously Reported	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Previously Reported	Noncontrolling Interest	Noncontrolling Interest Previously Reported
Common shares outstanding			84,924
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		$ 3,418,210		$ 1,982,164		$ 1,658,661		$ (235,463)		$ 12,848
Net income	$ 396,870				$ 397,400
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	174,220						$ 174,220
Stock Repurchased and Retired During Period, Shares			(127)
Stock Repurchased and Retired During Period, Value	(14,646)		$ (31,830)		17,184
Stock Issued During Period, Shares, Employee Stock Purchase Plans			556
Stock Issued During Period, Value, Employee Stock Purchase Plan	52,491		$ 52,491
Dividends, Common Stock, Cash	(133,837)				(133,837)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(4,179)								$ (4,179)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	2,258								2,258
Changes In Noncontrolling Interests, Other	81								81
Less: Net loss attributable to noncontrolling interests	(530)								(530)
Common shares outstanding			85,353
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,891,468		$ 2,002,825		1,939,408		(61,243)		10,478
Net income	242,870				243,888
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	(148,565)						(148,565)
Stock Repurchased and Retired During Period, Shares			(353)
Stock Repurchased and Retired During Period, Value	(55,777)		$ (34,894)		(20,883)
Stock Issued During Period, Shares, Employee Stock Purchase Plans			770
Stock Issued During Period, Value, Employee Stock Purchase Plan	67,499		$ 67,499
Dividends, Common Stock, Cash	(163,169)				(163,169)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(997)								(997)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	3,672								3,672
Changes In Noncontrolling Interests, Other	146								146
Less: Net loss attributable to noncontrolling interests	(1,018)								(1,018)
Noncontrolling Interest, Increase from Business Combination			14,297
Stock Issued During Period, Value, Acquisitions	2,689,317		$ 2,689,317
Consideration related to equity component of Cantel Convertible Debt	175,555		175,555
Consideration Related to Cantel Equity Compensation Programs	18,173		18,173
Reclassification to Cantel convertible debt, premium liability	$ (175,555)		$ (175,555)
Common shares outstanding	100,067		100,067
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 6,544,637		$ 4,742,920		1,999,244		(209,808)		12,281
Net income	105,813				107,030
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	(110,902)						(110,902)
Stock Repurchased and Retired During Period, Shares			(1,642)
Stock Repurchased and Retired During Period, Value	(308,565)		$ (297,322)		(11,243)
Stock Issued During Period, Shares, Employee Stock Purchase Plans			204
Stock Issued During Period, Value, Employee Stock Purchase Plan	40,777		$ 40,777
Dividends, Common Stock, Cash	(183,498)				(183,498)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(794)								(794)
Changes In Noncontrolling Interests, Other	(296)								(296)
Less: Net loss attributable to noncontrolling interests	$ (1,217)								(1,217)
Common shares outstanding	98,629		98,629
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 6,087,172		$ 4,486,375		$ 1,911,533		$ (320,710)		$ 9,974

CONSOLIDATED STATEMENTS OF SH_2

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.84	$ 1.69	$ 1.57

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Nature of Operations	1.NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, endoscopy accessories, barrier products, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati on. We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. We describe our business segments in Note 11 titled, "Business Segment Information." Our fiscal year ends on March 31. References in this Annual Report to a particular "year," "fiscal," "fiscal year," or "year-end" mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below. Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements. Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds, money market deposit accounts, bank savings accounts, and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity. Information supplementing our Consolidated Statements of Cash Flows is as follows: Years Ended March 31, 2023 2022 2021 Cash paid during the year for: Interest $ 108,470 $ 84,696 $ 36,257 Income taxes 254,661 138,382 109,646 Cash received during the year for income tax refunds 2,315 4,605 4,631 Revenue Recognition and Associated Liabilities. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At March 31, 2023, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During fiscal 2023, we recognized revenue of $78,752 that was included in our contract liability balance at the beginning of the period. During fiscal 2022, we recognized revenue of $46,760 that was included in our contract liability balance at the beginning of the period. Refer to Note 7 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 7 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of March 31, 2023, the transaction price allocated to remaining performance obligations was approximately $1,553,461 . We expect to recognize approximately 60% of the transaction price within one year and approximately 30% beyond one year. The remainder has yet to be scheduled for delivery. Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile. We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience. Inventories, net. Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead. We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to Cost of revenues. Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred. Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method. We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs. Interest. We capitalize interest costs incurred during the construction of long-lived assets. We capitalized interest costs of $6,366 and $3,886 for the years ended March 31, 2023 and 2022, respectively. Total interest expense for the years ended March 31, 2023, 2022, and 2021 was $107,989, $89,593, and $37,180, respectively. Identifiable Intangible Assets. Our identifiable intangible assets include product technology rights, trademarks, licenses, non-compete agreements, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. Determining the fair value of identifiable intangible requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates, among other items. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment. Investments. Investments in marketable securities are stated at fair value and are included in Other assets on the Consolidated Balance Sheets. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statements of Income. Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period. Asset Retirement Obligations. We incur retirement obligations for certain assets. We record initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 titled, “Property, Plant, and Equipment.” Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred. Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Management's judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other marketplace participants. Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience. Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis. We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 titled, “Benefit Plans.” Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.” Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statements of Income, except for certain intercompany balances designated as long-term in nature. Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including intercompany transactions.We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our Cost of revenues. We may also hold forward foreign exchange contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within Selling, general, and administrative expenses or Cost of revenues in the accompanying Consolidated Statements of Income. Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience. Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized. Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, general, and administrative expenses. We incurred $21,668, $15,599, and $6,795 of advertising costs during the years ended March 31, 2023, 2022, and 2021, respectively. Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues. Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate. We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 titled, “Income Taxes.” Share-Based Compensation. We describe share-based compensation in Note 14 titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as Cost of revenues, Selling, general, and administrative expenses or Research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statements of Income over the period during which an employee is required to provide service in exchange for the award. Restructuring. We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are re-evaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023. ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements. Standards that have not yet been adopted. ASU 2022-04 "Liabilities - Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations September 2022 The standard provides guidance to enhance the transparency of disclosures for entities that utilize supplier finance programs to include information about the key terms of the programs and present a rollforward of any obligations under the program where those obligations are presented in the balance sheet. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	12 Months Ended
	Mar. 31, 2023
Business Combinations and Divestitures [Abstract]
Business Combination Disclosure [Text Block]	2. BUSINESS ACQUISITIONS AND DIVESTITURES Fiscal 2023Acquisitions During fiscal 2023, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Applied Sterilization Technologies and Healthcare segments. Total aggregate consideration was approximately $49,842, including potential contingent consideration of $7,269. Purchase price allocations will be finalized within the measurement period not to exceed one year from closing. Fiscal 2022 Acquisition of Cantel Medical LLC On June 2, 2021, we acquired all outstanding equity interests in Cantel Medical LLC ("Cantel") through a U.S. subsidiary. Cantel, formerly headquartered in Little Falls, New Jersey, with approximately 3,700 employees, is a global provider of infection prevention products and services primarily to endoscopy and dental Customers. We believe that the acquisition will strengthen STERIS’s leadership in infection prevention by bringing together two complementary businesse s able to offer a broader set of Customers a more diversified selection of infection prevention, endoscopy and sterilization products and services. Cantel’s Dental business extended our business into a new Customer segment where there is an increasing focus on infection prevention protocols and processes. This business is reported as the Dental segment. The rest of Cantel was integrated into our existing Healthcare and Life Sciences segments. Additionally, the acquisition is expected to result in cost savings from optimizing global back-office infrastructure, leveraging best-demonstrated practices across locations and eliminating redundant public company costs. Total Purchase Consideration The total consideration for Cantel Common Stock and stock equivalents was $3,599,471. The consideration was comprised of the following: (shares in thousands) Cash consideration $16.93 per Cantel share (42,816 shares) $ 716,412 Cash consideration for fractional shares 14 STERIS plc ordinary shares 14,297 shares at ($188.07 per share) 2,689,317 Consideration related to Cantel equity compensation programs 18,173 Consideration related to equity component of Cantel convertible debt 175,555 Total purchase consideration $ 3,599,471 In addition, STERIS assumed and repaid $721,284 of existing Cantel debt obligations and assumed Cantel's obligations associated with convertible senior notes issued on May 15, 2020, which is described in Note 6 titled, " Debt ." We funded the cash portion of the transaction consideration and repayment of a significant amount of Cantel’s existing debt obligations with a portion of the proceeds from new debt, which is described in Note 6 titled, " Debt. " Fair Value of Assets Acquired and Liabilities Assumed The acquisition of Cantel has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired and liabilities assumed be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. Goodwill has been allocated to the Healthcare, Dental and Life Sciences segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill recognized as a result of the acquisition is not deductible for tax purposes. During the second quarter of fiscal 2023, in connection with the preparation of our quarterly consolidated financial statements, we identified and recognized a goodwill impairment loss of $490,565 related to goodwill that arose with respect to assets acquired in the Cantel acquisition. For more information on the impairment loss, see Note 3 to our consolidated financial statements titled, "Goodwill and Intangible Assets." The table below presents the allocation of the purchase price to the net assets acquired based on the fair values at the acquisition date. March 31, 2022 Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant, and equipment 267,360 (1,282) 266,078 Lease right-of-use assets 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471 Cantel Other Intangible Assets The estimated fair values of identifiable intangible assets were prepared using income valuation methodologies, which require a forecast of expected future cash flows using either the relief-from-royalty method or the multi-period excess earnings method. The estimated useful lives are based on the historical experience of STERIS, available similar industry data and assumptions made by management.Values and useful lives are presented in the table below. Total Useful Life Customer relationships $ 2,278,000 9-10 years Trade names 422,000 11 years Developed technology 222,000 9 years Non-compete agreements 20,000 2 years Total intangible assets acquired $ 2,942,000 Contingent liabilities assumed totaled $25,000 and were related to contingent consideration associated with a prior acquisition completed by Cantel. Payment was made in June, 2021. Actual and Pro Forma Impact Our consolidated financial statements for fiscal 2022 include Cantel's results of operations from the date of acquisition on June 2, 2021 through March 31, 2022. Net sales and operating income attributable to Cantel from the date of acquisition and included in our consolidated financial statements for the fiscal year ended March 31, 2022 total $974,408 and $41,757, respectively. The following unaudited pro forma information gives effect to our acquisition of Cantel as if the acquisition had occurred on April 1, 2020 and Cantel had been included in our consolidated results of operations for the fiscal years ended March 31, 2022 and 2021. Fiscal Year Ended March 31, (unaudited) 2022 2021 Net revenues $ 4,790,161 $ 4,190,244 Net income from continuing operations 449,382 5,849 The historical consolidated financial information of STERIS and Cantel has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the transaction and factually supportable. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental depreciation and amortization to be reported based on the latest draft of valuations of assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings. Other Fiscal 2022 Acquisitions In addition to the acquisition of Cantel, we completed three other tuck-in acquisitions during fiscal 2022, which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration for these transactions was approximately $3,146, net of cash acquired and including deferred consideration of $50. Fiscal 2021 Acquisitions On January 4, 2021 , we purchased the remaining outstanding shares of an entity in which we had initially made an equity investment in fiscal 2019. Total consideration was approximately $78,045, net of cash acquired and subject to any working capital adjustments. Total non-cash consideration for this transaction was $41,771, which consisted of the settlement of outstanding principal and interest on a loan receivable, the initial equity investment, and receivables related to capital equipment purchases that existed at the acquisition date. The business has been integrated into our Applied Sterilization Technologies business segment and we funded the transaction through a combination of cash on hand and credit facility borrowings. On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical has been integrated into our Healthcare segment. The total purchase price of the acquisition was $853,203, net of cash acquired and remains subject to customary working capital adjustments. The purchase price for the acquisition was financed with a combination of cash on hand, credit facility borrowings and proceeds from borrowings under a then new Term loan agreement. Please refer to Note 6 titled, "Debt" for more information. We also completed two other tuck-in acquisitions during fiscal 2021, which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration for these transactions was approximately $20,909, net of cash acquired and including deferred consideration of approximately $1,194. Fair Value of Assets Acquired and Liabilities Assumed The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2023, 2022 and 2021 acquisitions. Fiscal Year 2023 (1) Fiscal Year 2022 Fiscal Year 2021 (2) (dollars in thousands) All Acquisitions Other Acquisitions (Excluding Cantel) Key Surgical Other Acquisitions Cash $ — $ — $ 12,615 $ 9,159 Accounts receivable 2,405 — 13,967 9,621 Inventory 12,342 — 21,414 22,123 Property, plant, and equipment 2,131 — 6,030 26,363 Lease right-of-use assets, net 667 — 4,907 4,420 Other assets 177 — 6,680 3,378 Intangible assets (2) 27,576 1,578 356,999 28,188 Goodwill 7,024 1,602 527,675 42,808 Total assets 52,322 3,180 950,287 146,060 Current liabilities (2,007) (34) (21,599) (28,245) Non-current liabilities (473) — (62,870) (9,704) Total liabilities (2,480) (34) (84,469) (37,949) Net assets $ 49,842 $ 3,146 $ 865,818 $ 108,111 (1) Purchase price allocation is still preliminary as of March 31, 2023 for certain acquisitions, as valuations have not been finalized, pending further analyses of the significant drivers of fair value. (2) The Fiscal 2021 amount includes $315,575, related to the fair value of the Customer relationships intangible asset obtained in the acquisition of Key Surgical. The estimation of fair value was determined under an income approach using discounted cash flows. The estimate requires assumptions including forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. The deductible portion of goodwill for tax purposes recognized as a result of the fiscal 2023, 2022 and fiscal 2021 acqu isitions wa s $4,863, $427,035 and $197,344, respectively. Acquisition related transaction and integration costs totaled $24,196, $205,788 , and $35,634 for the fiscal years ended March 31, 2023 , 2022, and 2021, respectively. Fiscal 2022 acquisition and integration expenses were primarily related to the acquisition of Cantel. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income. Divestitures Fiscal 2023 Divestitures. In April 2022, we entered into an Asset Purchase Agreement to sell certain assets of our Animal Health business to Veterinary Orthopedic Implants, LLC. We recorded net proceeds of $5,228 and recognized a pre-tax loss on the sale of $4,852 in the Selling, general, and administrative expenses line of the Consolidated Statements of Income. The business generated annual revenues of approximately $12,000. Fiscal 2022 In December 2021, we entered into an Asset Purchase Agreement to sell our Renal Care business to Evoqua Water Technologies Corp., for cash consideration of approximately $196,000, subject to certain potential adjustments, including a customary working capital adjustment and contingent consideration of $12,300. We recognized a pre-tax gain on the sale of $4,919. The transaction closed on January 3, 2022. We acquired the Renal Care business as part of the Cantel transaction, which closed on June 2, 2021, and had been integrated into STERIS's Healthcare segment. The Renal Care business generated annual revenues of approximately $180,000. The proceeds from the sale received at closing were used to repay outstanding debt. During the third quarter of fiscal 2023, we received an additional $1,396 in working capital settlements related to the sale of this business. Fiscal 2021

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	3.GOODWILL AND INTANGIBLE ASSETS Changes to the carrying amount of goodwill for the years ended March 31, 2023 and 2022 were as follows: Healthcare Applied Sterilization Technologies Segment Life Sciences Dental Total Balance at March 31, 2021 1,384,763 1,492,239 149,047 — 3,026,049 Cantel goodwill acquired 1,019,332 — 30,356 472,693 1,522,381 Measurement period adjustments to acquired goodwill (6,533) (9,286) — — (15,819) Divestitures (7,000) — — — (7,000) Foreign currency translation adjustments and other (63,732) (50,095) (115) (7,326) (121,268) Balance at March 31, 2022 $ 2,326,830 $ 1,432,858 $ 179,288 $ 465,367 $ 4,404,343 Goodwill acquired 6,221 803 — — 7,024 Measurement period adjustments to acquired goodwill (21,624) — 3,147 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments and other (7,796) (37,527) (623) (15,367) (61,313) Balance at March 31, 2023 $ 2,301,273 $ 1,396,134 $ 181,812 $ — $ 3,879,219 See Note 2 titled, "Business Acquisitions and Divestitures," for additional information regarding our recent business acquisitions and divestitures. We evaluate the recoverability of recorded goodwill annually at the reporting unit level during the third fiscal quarter, or when evidence of potential impairment exists. The Company's reporting units are equivalent to the reportable operating segments. In connection with the preparation of our second quarter consolidated financial statements, we considered the risk of impairment due to deteriorating macroeconomic conditions including rising interest rates and inflationary pressures on material and labor costs, as well as uncertainty regarding the impact such economic strains will have on patient and Customer behavior in the short-term. Our conclusion, based on the qualitative assessment of these factors, was that it was more likely than not that the goodwill allocated to the Dental segment as of September 30, 2022 was impaired. Our quantitative analysis to measure the extent of goodwill impairment compared the estimated fair value to the carrying value of the Dental segment. The fair value is estimated as the present value of future cash flows. Future cash flow projections are consistent with those used in our forecasting and strategic planning processes. The determination of the discount rate requires judgement and assumptions to be developed about the weighted average cost of capital that market participants would employ in evaluating the current fair value of the business. The macroeconomic factors that triggered the interim review are also the drivers of the increase in the weighted average cost of capital assumption. In connection with the preparation of our second quarter consolidated financial statements, we identified that the estimated fair value of the Dental segment was below the carrying value and recognized a non-cash goodwill impairment charge of $490,565. The impairment charge was recorded within "Goodwill impairment loss" in the Consolidated Statements of Income during the second quarter of fiscal 2023. Our review as of the second quarter of fiscal 2023 did not indicate that impairment of goodwill was more likely than not for any of the remaining segments during the period. The annual goodwill impairment review was conducted in the third quarter of fiscal 2023 as planned. No additional goodwill impairment was identified during this review. As a result of our annual impairment review of goodwill for fiscal years 2022 and 2021, no indicators of impairment were identified. Information regarding our intangible assets is as follows: 2023 2022 March 31, Gross Accumulated Gross Accumulated Customer relationships $ 3,099,544 $ 818,810 $ 3,117,314 $ 539,845 Non-compete agreements 23,486 21,535 23,571 12,392 Patents and technology 534,539 252,809 518,714 211,822 Trademarks and tradenames 468,729 111,158 470,919 74,455 Supplier relationships 54,800 21,006 54,800 18,267 Total $ 4,181,098 $ 1,225,318 $ 4,185,318 $ 856,781 Certain trademarks and tradenames obtained as a result of business combinations are indefinite-lived assets. The approximate carrying value of these assets at March 31, 2023 and March 31, 2022 was $14,250. We evaluate our indefinite-lived intangible assets annually during the third quarter or when evidence of potential impairment exists. No impairment was recognized for fiscal years 2023, 2022 or 2021. Total amortization expense for intangible assets was $379,752, $368,698, and $86,512 for the years ended March 31, 2023, 2022, and 2021, respectively. Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows: 2024 2025 2026 2027 2028 Estimated amortization expense $ 369,358 $ 363,499 $ 354,672 $ 348,506 $ 343,510 The estimated annual amortization expense presented in the preceding table has been calculated based upon March 31, 2023 currency exchange rates.

Inventories, Net

Inventories, Net	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Inventories, Net	4.INVENTORIES, NET Components of our inventories are presented in the following table. March 31, 2023 2022 Raw materials $ 239,081 $ 195,035 Work in process 97,756 76,021 Finished goods 404,238 334,880 Reserve for excess and obsolete inventory (45,582) (30,937) Inventories, net $ 695,493 $ 574,999

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Property, Plant and Equipment	5.PROPERTY, PLANT, AND EQUIPMENT Information related to the major categories of our depreciable assets is as follows: March 31, 2023 2022 Land and land improvements (1) $ 84,313 $ 84,015 Buildings and leasehold improvements 691,933 654,851 Machinery and equipment 994,188 903,649 Information systems 247,873 222,620 Radioisotope 637,920 597,641 Construction in progress (1) 478,316 356,013 Total property, plant, and equipment 3,134,543 2,818,789 Less: accumulated depreciation and depletion (1,429,031) (1,266,213) Property, plant, and equipment, net $ 1,705,512 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service. Depreciation and depletion expense were $173,145, $184,406 and $132,725, for the years ended March 31, 2023, 2022, and 2021, respectively. Asset Retirement Obligations We provide contract sterilization services including Gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the future disposal of these assets once depleted. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis. The following table summarizes the activity in the liability for asset retirement obligations. Asset Retirement Obligations Balance at March 31, 2021 $ 13,330 Liabilities incurred during the period 86 Liabilities settled during the period (3) Accretion expense and change in estimate 146 Foreign currency and other (16) Balance at March 31, 2022 $ 13,543 Liabilities incurred during the period 86 Liabilities settled during the period (625) Accretion expense and change in estimate 104 Foreign currency and other 23 Balance at March 31, 2023 $ 13,131

Debt

Debt	12 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	6.DEBT Indebtedness as of March 31, 2023 and 2022 was as follows: March 31, March 31, Short-term debt Term loan, current portion $ 27,500 $ 27,500 Delayed draw term loan, current portion 32,500 24,375 Private Placement Senior Notes — 91,000 Total short-term debt $ 60,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 750,302 $ 758,726 Revolving Credit Facility 301,672 58,908 Deferred financing costs (21,444) (25,278) Term loan 45,000 177,500 Delayed draw term loan 593,125 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,018,655 $ 2,945,481 Total debt $ 3,078,655 $ 3,088,356 On March 19, 2021, STERIS plc ("the Company"), STERIS Corporation, STERIS Limited (“Limited”), and STERIS Irish FinCo Unlimited Company ("FinCo", "STERIS Irish FinCo"), each as a borrower and guarantor, entered into a credit agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Revolving Credit Agreement”) providing for a $1,250,000 revolving credit facility (the “Revolver”), which replaced a prior revolving credit agreement. The Revolver provides for revolving credit borrowings, swing line borrowings and letters of credit, with sublimits for swing line borrowings and letters of credit. The Revolver may be increased in specified circumstances by up to $625,000 in the discretion of the lenders. The Revolver matures on the date that is five years after March 19, 2021, and all unpaid borrowings, together with accrued and unpaid interest thereon, are repayable on that date. The Revolver bears interest from time to time, at either the Base Rate, the applicable Relevant Rate, or the applicable Adjusted Daily Simple RFR, as defined in and calculated under and as in effect from time to time under the Revolving Credit Agreement, plus the Applicable Margin, as defined in the Revolving Credit Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Credit Agreement. Interest on Base Rate Advances is payable quarterly in arrears, interest on Term Benchmark Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months, and interest on RFR Advances is payable monthly after the date of borrowing. Swingline borrowings bear interest at a rate to be agreed upon by the applicable swingline lender and the applicable borrower, subject to a cap in the case of swingline borrowings denominated in U.S. Dollars equal to the Base Rate plus the Applicable Margin for Base Rate Advances plus the Facility Fee. Advances may be extended in U.S. Dollars or in specified alternative currencies. In connection with the cessation of British Pound Sterling LIBOR and Swiss Franc LIBOR as of December 31, 2021, JPMorgan Chase Bank, N.A. as administrative agent, pursuant to authority contained in the Revolver, amended the Revolver on January 1, 2022 to make Benchmark Replacement Conforming Changes (as defined in the Revolver). The amendment concerns technical, administrative or operational changes related to borrowings in British Pounds Sterling and Swiss Francs. As of March 31, 2023 a total of $301,672 of Credit Agreement and Swing Line Facility borrowings were outstanding under the Credit Agreement, based on currency exchange rates as of March 31, 2023. On March 19, 2021, the Company, STERIS Corporation, Limited, and FinCo, each as a borrower and guarantor, entered into a term loan agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Term Loan Agreement”) providing for a $550,000 term loan facility (the “Term Loan”), which replaced an existing term loan agreement, dated as of November 18, 2020 (the “Existing Term Loan Agreement”). The proceeds of the Term Loan were used to refinance the Existing Term Loan Agreement. The Term Loan matures on the date that is five years after March 19, 2021 (the “Term Loan Closing Date”). No principal payments are due on the Term Loan for the period beginning from the first full fiscal quarter ended after the Term Loan Closing Date to and including the fourth full fiscal quarter ended after the Term Loan Closing Date. For the period beginning from the fifth full fiscal quarter ended after the Term Loan Closing Date to and including the twelfth full fiscal quarter ended after the Term Loan Closing Date, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. For the period beginning from the thirteenth full fiscal quarter ended after the Term Loan Closing Date through the maturity of the loan, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal is due and payable on the maturity date. The Term Loan bears interest from time to time, at either the Base Rate or the Adjusted Term SOFR Rate, as defined in and calculated under and as in effect from time to time under the Term Loan Agreement, plus the Applicable Margin, as defined in the Term Loan Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Term Loan Agreement. Interest on Base Rate Advances is payable quarterly in arrears and interest on Term Benchmark Advances is payable in arrears at the end of the relevant interest period therefor, but in no event less frequently than every three months. Also on March 19, 2021, the Company, STERIS Corporation, Limited, and FinCo, each as a borrower and guarantor, entered into a delayed draw term loan agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Delayed Draw Term Loan Agreement”) providing for a delayed draw term loan facility of up to $750,000 (the “Delayed Draw Term Loan”) in connection with STERIS’s acquisition of Cantel. During the first quarter of fiscal 2022, we borrowed $650,000 under our Delayed Draw Term Loan Agreement. The Delayed Draw Term Loan was funded by the lenders upon consummation of the Cantel acquisition (the “Acquisition Closing Date”). The proceeds of the Delayed Draw Term Loan were used, together with the proceeds from other new indebtedness, to fund the cash consideration for the acquisition, as well as for various other items. The Delayed Draw Term Loan matures on the date that is five years after the Acquisition Closing Date. No principal payments are due on the Delayed Draw Term Loan for the period beginning from the first full fiscal quarter ended after the Acquisition Closing Date to and including the fourth full fiscal quarter ended after the Acquisition Closing Date. For the period beginning from the fifth full fiscal quarter ended after the Acquisition Closing Date to and including the twelfth full fiscal quarter ended after the Acquisition Closing Date, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Delayed Draw Term Loan, are due on the last business day of each fiscal quarter. For the period beginning from the thirteenth full fiscal quarter ended after the Acquisition Closing Date through the maturity of the loan, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Delayed Draw Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal is due and payable on the maturity date. The Delayed Draw Term Loan bears interest from time to time, at either the Base Rate or the Adjusted Term SOFR Rate, as defined in and calculated under and as in effect from time to time under the Delayed Draw Term Loan Agreement, plus the Applicable Margin, as defined in the Delayed Draw Term Loan Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Delayed Draw Term Loan Agreement. Interest on Base Rate Advances is payable quarterly in arrears and interest on Term Benchmark Advances is payable in arrears at the end of the relevant interest period therefor, but in no event less frequently than every three months. On May 3, 2023, in connection with the upcoming replacement of U.S. dollar LIBOR with SOFR, the Borrower, Guarantors, Lenders, and JPMorgan Chase Bank, N.A., each as defined in each of the agreements, amended the Revolving Credit Agreement, the Term Loan Agreement, and the Delayed Draw Term Loan Agreement. The amendments concern pricing, technical, administrative, and operational changes related to borrowings in U.S. dollars. The above descriptions reflect those amendments. Senior Public Notes On April 1, 2021, STERIS Irish FinCo Unlimited Company ("FinCo," "STERIS Irish FinCo," the "Issuer") completed an offering of $1,350,000 in aggregate principal amount, of its senior notes in two separate tranches: (i) $675,000 aggregate principal amount of the Issuer’s 2.70% Senior Notes due 2031 (the “2031 Notes”) and (ii) $675,000 aggregate principal amount of the Issuer’s 3.750% Senior Notes due 2051 (the “2051 Notes” and, together with the 2031 Notes, the “Senior Public Notes”). The Senior Public Notes were issued pursuant to an Indenture, dated as of April 1, 2021 (the “Base Indenture”), among FinCo, and STERIS plc, STERIS Corporation and STERIS Limited (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture, dated as of April 1, 2021, among FinCo, the Guarantors and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”). Each of the Guarantors guaranteed the Senior Public Notes jointly and severally on a senior unsecured basis (the “Guarantees”). The 2031 Notes will mature on March 15, 2031 and the 2051 Notes will mature on March 15, 2051. The Senior Public Notes will bear interest at the rates set forth above. Interest on the Senior Public Notes is payable on March 15 and September 15 of each year, beginning on September 15, 2021, until their respective maturities. Cantel's Convertible Debt On May 15, 2020, Cantel issued $168,000 aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private placement. The initial conversion price was $41.51 per share of Cantel common stock (based on an initial conversion rate of 24.0912 shares of Cantel common stock per one thousand dollars in principal amount of Notes) and was, along with the conversion rate, subject to adjustment if certain events occurred. On June, 3, 2021, Cantel (a) delivered a notice to holders of its Notes pursuant to the indenture governing the Notes (as supplemented, the "Cantel Indenture”), notifying holders that, as a result of each of (i) the consummation of the series of mergers (the “Mergers”) contemplated by the Agreement and Plan of Merger, dated as of January 12, 2021 (as amended by Amendment to Agreement and Plan of Merger, dated as of March 1, 2021), among Cantel, STERIS plc (“Parent”), Solar New US Holding Co, LLC (now known as Solar New US Holding Corporation) (“US Holdco”), an indirect and wholly owned subsidiary of Parent, and Crystal Merger Sub 1, LLC, a direct and wholly owned subsidiary of US Holdco, and (ii) the delisting of Cantel common stock from the New York Stock Exchange (the “NYSE”), a “Fundamental Change” and a “Make-Whole Fundamental Change,” each as defined in the Cantel Indenture, had occurred effective as of June 2, 2021 and (b) commenced an offer to purchase any and all outstanding Notes as a result of the Fundamental Change. A tender offer statement on Schedule TO (“Schedule TO”) was filed by Cantel with the U.S. Securities and Exchange Commission ("SEC") with respect to the right of each holder (each, a “Holder”) of the Notes to require Cantel to repurchase, at the Holder’s option, 100% of the principal amount of the Notes, plus accrued and unpaid interest thereon to, but excluding the settlement date of July 6, 2021 (as such date was amended by Amendment No. 1 to Schedule TO (“Amendment No. 1”), dated June 29, 2021). The offer to purchase the Notes expired at 11:59 p.m. New York City time, on July 1, 2021 (the “Expiration Time,” as such date was amended by Amendment No. 1), and was not extended. Wells Fargo Bank, National Association, as paying agent and trustee under the Indenture (the “Cantel Trustee”), informed Cantel that as of the Expiration Time, none of the Notes had been validly tendered (and not properly withdrawn) for purchase. Pursuant to the terms of the Cantel Indenture, in connection with the consummation of the Mergers, Cantel, Parent and the Cantel Trustee entered into a supplemental indenture providing that, following the Mergers, each holder’s right to convert each one thousand dollar principal amount of Notes into shares of Cantel common stock was changed into a right to convert such principal amount of Notes into the kind and amount of cash, stock, other securities, other property or assets, subject to settlement method election provisions of the Indenture, that a holder of Cantel common stock was entitled to receive upon consummation of the Mergers. At the consummation of the Mergers, holders of Cantel common stock received $16.93 in cash and 0.33787 ordinary shares, par value $0.001 per share, of the Parent (“Parent Shares”) for each share of Cantel common stock (each a “unit of Reference Property”). Because each of the consummation of the Mergers and the delisting of Cantel common stock from the NYSE constituted a “Make-Whole Fundamental Change” under the Cantel Indenture, any Notes surrendered for conversion from and including June 2, 2021 until July 2, 2021 (the “Make-Whole Conversion Period”) were subject to conversion at the conversion rate of 25.0843 units of Reference Property (the “Make-Whole Conversion Rate”), which corresponded to 8.4752 Parent Shares and approximately $424.68 in cash per one thousand dollars in principal amount of Cantel Notes. The Make-Whole Conversion Rate was based on an increase in the Conversion Rate by 0.9931 Additional Shares (as defined in the Indenture) based on a Make-Whole Effective Date of June 2, 2021 and a Stock Price (each as defined in the Indenture) of $81.3520. Cantel settled all conversions of Notes in connection with the Make-Whole Fundamental Changes that constituted the Mergers and delisting of Cantel common stock from the NYSE pursuant to the Cash Settlement provisions of the Cantel Indenture. The Cantel Trustee, acting as conversion agent, informed Cantel that holders of 100% of the outstanding Notes elected to convert their Notes during the Make-Whole Conversion Period. The fair value of the Notes exceeded their aggregate par value of $168,000 at the date of consummation of the Mergers. The fair value was estimated utilizing the closing price of Parent Shares on June 2, 2021. A premium of approximately $175,555 in excess of the aggregate par value of the Notes represented purchase consideration and was initially classified in additional paid-in capital in accordance with ASC 2020-06, "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)." Because all Holders elected to convert during the Make-Whole Conversion Period, the aggregate par value outstanding was reclassified to current liabilities in the balance sheet. The premium initially recorded as additional paid in capital at the effective time of the Mergers was reclassified to "Convertible debt, premium liability," also classified as a current liability, and was settled in cash. The final total Cash Settlement value of the Notes was approximately $371,361, comprised of the aggregate par value of $168,000 and the fair value of the liability representing the premium over par of approximately $203,361. The liability representing the premium over par value increased between the effective date of the Mergers and settlement because of the movement in trading prices of Parent Shares during the Observation Periods. The fluctuation in fair value during such Observation Periods is reported in the statement of income as a component of “Non-operating expense, net.” Our outstanding Private Placement Senior Notes at March 31, 2023 and 2022 were as follows: Applicable Note Purchase Agreement Maturity Date U.S. Dollar Value at March 31, 2023 U.S. Dollar Value at March 31, 2022 $91,000 Senior notes at 3.20% 2012 Private Placement December 2022 — 91,000 $80,000 Senior notes at 3.35% 2012 Private Placement December 2024 80,000 80,000 $25,000 Senior notes at 3.55% 2012 Private Placement December 2027 25,000 25,000 $125,000 Senior notes at 3.45% 2015 Private Placement May 2025 125,000 125,000 $125,000 Senior notes at 3.55% 2015 Private Placement May 2027 125,000 125,000 $100,000 Senior notes at 3.70% 2015 Private Placement May 2030 100,000 100,000 $50,000 Senior notes at 3.93% 2017 Private Placement February 2027 50,000 50,000 €60,000 Senior notes at 1.86% 2017 Private Placement February 2027 65,254 66,815 $45,000 Senior notes at 4.03% 2017 Private Placement February 2029 45,000 45,000 €20,000 Senior notes at 2.04% 2017 Private Placement February 2029 21,752 22,271 £45,000 Senior notes at 3.04% 2017 Private Placement February 2029 55,579 59,089 €19,000 Senior notes at 2.30% 2017 Private Placement February 2032 20,664 21,158 £30,000 Senior notes at 3.17% 2017 Private Placement February 2032 37,053 39,393 Total Senior Notes $ 750,302 $ 849,726 On February 27, 2017, Limited issued and sold an aggregate principal amount of $95,000, €99,000, and £75,000, of senior notes in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of between 10 years and 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants. On May 15, 2015, STERIS Corporation issued and sold $350,000 of senior notes, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of 10 years to 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants. In December 2012, and in February 2013 STERIS Corporation issued and sold $200,000 of senior notes, in a private placement to certain institutional investors in offerings that were exempt from the registration requirements of the Securities Act of 1933. The agreement governing the notes contains leverage and interest coverage covenants. The private placement note purchase agreements specify increases to the coupon interest rates while the ratio of Consolidated Total Debt to Consolidated EBITDA, as defined in the note purchase agreements, exceeds certain thresholds. Beginning September 1, 2021 and through March 31, 2023, the coupon rates on the 2012 private placement notes were increased by 0.50%. On March 19, 2021, STERIS Corporation as issuer, and the Company, Limited and FinCo, as guarantors, entered into (1) a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated certain note purchase agreements originally dated December 4, 2012) per the 2012 and 2013 senior notes (the “2012 Amendment”), and (2) a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated certain note purchase agreements originally dated March 31, 2015) for the 2015 senior notes (the “2015 Amendment”). Also on March 19, 2021, Limited, as Issuer, and the Company, STERIS Corporation and FinCo, as guarantors, entered into a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated a certain note purchase agreement originally dated January 23, 2017) for the 2017 senior notes (together with the 2012 Amendment and the 2015 Amendment, the “NPA Amendments”). The NPA Amendments provided, among other things, for the waiver of certain repurchase rights of the note holders and increased the size of certain baskets to more closely align with other current credit agreement baskets. At March 31, 2023, we were in compliance with all financial covenants associated with our indebtedness. The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows: 2024 $ 60,000 2025 165,938 2026 479,173 2027 614,942 2028 and thereafter 1,780,047 Total $ 3,100,100

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	7.ADDITIONAL CONSOLIDATED BALANCE SHEET INFORMATION Additional information related to our Consolidated Balance Sheets is as follows: March 31, 2023 2022 Accrued payroll and other related liabilities: Compensation and related items $ 48,565 $ 71,878 Accrued vacation/paid time off 11,080 13,669 Accrued bonuses 33,605 64,702 Accrued employee commissions 29,257 30,171 Other post-retirement benefits obligations-current portion 1,121 1,190 Other employee benefit plans' obligations-current portion 2,014 2,111 Total accrued payroll and other related liabilities $ 125,642 $ 183,721 Accrued expenses and other: Deferred revenues $ 92,283 $ 110,791 Service liabilities 72,033 51,365 Self-insured and related risk reserves-current portion 11,325 8,995 Accrued dealer commissions 31,096 31,700 Accrued warranty 13,683 14,108 Asset retirement obligation-current portion 543 1,181 Accrued interest 9,243 10,014 Other 87,611 78,390 Total accrued expenses and other $ 317,817 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 22,171 $ 19,213 Other post-retirement benefits obligations-long-term portion 6,070 7,335 Defined benefit pension plans obligations-long-term portion 2,876 1,772 Other employee benefit plans obligations-long-term portion 1,153 1,360 Accrued long-term income taxes 10,082 12,225 Asset retirement obligation-long-term portion 12,588 12,362 Other 21,197 21,312 Total other liabilities $ 76,137 $ 75,579

Income Tax Expense

Income Tax Expense	12 Months Ended
	Mar. 31, 2023
Income Tax Expense [Abstract]
Income Tax Expense (Benefit)	8.INCOME TAXES Income from continuing operations before income taxes was as follows: Years Ended March 31, 2023 2022 2021 United States operations $ (16,759) $ 79,662 $ 326,991 Ireland operations 62,664 88,078 73,442 Other locations operations 111,443 146,763 117,100 $ 157,348 $ 314,503 $ 517,533 The components of the provision for income taxes related to income from continuing operations consisted of the following: Years Ended March 31, 2023 2022 2021 Current: United States federal $ 138,208 $ 88,158 $ 57,550 United States state and local 33,234 21,438 16,272 Ireland 8,837 12,002 9,244 Other locations 61,446 53,354 36,699 241,725 174,952 119,765 Deferred: United States federal (114,523) (73,833) 7,523 United States state and local (50,530) (17,124) (550) Ireland (864) (739) (787) Other locations (24,273) (11,623) (5,288) (190,190) (103,319) 898 Total Provision for Income Taxes $ 51,535 $ 71,633 $ 120,663 The total provision for income taxes can be reconciled to the tax computed at the Ireland statutory tax rate as follows: Years Ended March 31, 2023 2022 2021 National statutory tax rate 12.5 % 12.5 % 12.5 % (Decrease) increase in accruals for uncertain tax positions (0.1) % 0.2 % (0.1) % U.S. state and local taxes, net of federal income tax benefit (10.8) % 1.4 % 2.4 % (Decrease) increase in valuation allowances (0.1) % 0.9 % 0.3 % U.S. research and development credit (1.8) % (0.8) % (0.5) % U.S. foreign income tax credit (1.2) % (1.1) % (0.3) % Difference in non-Ireland tax rates 8.6 % 12.6 % 8.3 % U.S. federal audit adjustments — % — % 2.1 % Impairment of nondeductible goodwill 29.0 % — % — % Excess tax benefit for equity compensation (2.7) % (5.1) % (1.9) % Tax rate changes on deferred tax assets and liabilities 0.4 % 2.3 % 0.4 % U.S. tax reform impact, GILTI and FDII (1.3) % (0.9) % (0.6) % Capitalized acquisition, redomiciliation costs — % 1.8 % 0.6 % All other, net 0.3 % (1.0) % 0.1 % Total Provision for Income Taxes 32.8 % 22.8 % 23.3 % Unrecognized Tax Benefits. We classify uncertain tax positions and related interest and penalties as long-term liabilities within “Other liabilities” in our accompanying Consolidated Balance Sheets, unless they are expected to be paid within 12 months, in which case, the uncertain tax positions would be classified as current liabilities within “Accrued income taxes.” We recognize interest and penalties related to unrecognized tax benefits within “Income tax expense” in our accompanying Consolidated Statements of Income. A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows: 2023 2022 Unrecognized Tax Benefits Balance at April 1 $ 2,906 $ 2,295 Increases for tax provisions of current year 63 — Decreases for tax provisions of prior year — (135) Balances related to acquired/disposed businesses (503) 746 Other, including currency translation 21 — Unrecognized Tax Benefits Balance at March 31 $ 2,487 $ 2,906 We recognized interest and penalties related to uncertain tax positions in the provision for income taxes. As of March 31, 2023 and 2022, we had $152 and $152 accrued for interest and penalties, respectively. If all unrecognized tax benefits were recognized, the net impact on the provision for income tax expense would be $2,640. The increase in unrecognized tax benefits from prior year is due to the additions of new positions. It is reasonably possible that during the next 12 months, there will be no material reductions in unrecognized tax benefits as a result of the expiration of various statutes of limitations or other matters. We operate in numerous t axing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2018 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2017. W e remain subject to tax authority audits in various jurisdictions wherever we do business. In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 through 2017. An agreement was reached on final interest rates, which also impacts subsequent years through 2020. We estimate the total federal, state, and local tax impact of the settlement to be approximately $12,000, for the fiscal years 2016 through 2020, of which approximately $7,500 has been paid through March 31, 2023. In May 2021, we received two notices of proposed tax adjustment from the IRS regarding deemed dividend inclusions and associated withholding tax. The notices relate to the fiscal and calendar year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50,000. We are contesting the IRS’s assertions. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but it could be material to our consolidated results of operations and cash flows for any one period. We estimate that the tax benefit from our Costa Rican Tax Holiday is $2,000 (or $0.02 per fully diluted share), annually. The Tax Holiday runs fully exempt from income tax through 2025, and partially exempt through 2029. Deferred Taxes. The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2023 and 2022 were as follows: March 31, 2023 2022 Deferred Tax Assets: Post-retirement benefit accrual $ 1,737 $ 2,086 Compensation 15,858 14,340 Net operating loss carryforwards 37,667 25,550 Accrued expenses 13,150 12,092 Insurance 2,268 2,561 Deferred income 23,967 20,688 Bad debt 3,763 2,187 Research & experimental expenditures 15,382 — Operating leases (1) 46,781 44,401 Foreign tax credit carryforwards 33,559 36,036 Other 11,701 8,579 Deferred Tax Assets 205,833 168,520 Less: Valuation allowance 20,315 24,691 Total Deferred Tax Assets 185,518 143,829 Deferred Tax Liabilities: Depreciation and depletion 98,601 110,951 Operating leases (1) 45,834 43,593 Intangibles 630,589 755,980 Pension 2,644 2,004 Other 3,186 3,473 Total Deferred Tax Liabilities 780,854 916,001 Net Deferred Tax Assets (Liabilities) $ (595,336) $ (772,172) (1) For more information regarding our operating leases, see Note 10 titled, "Commitments and Contingencies." At March 31, 2023, we had U.S. federal operating loss carryforwards of $9,407, which remain subject to a 20 year carryforward period. Additionally, we had non-U.S. operating loss carry forwards of $126,443. Although the majority of the non-U.S. carryforwards have indefinite expiration periods, those carryforwards that have definite expiration periods will expire if unused between fiscal years 2024 and 2044. In addition, we have recorded pre-valuation allowance tax benefits of $3,391 related to state operating loss carryforwards. If unused, these state operating loss carryforwards will expire between fiscal years 2024 and 2044. At March 31, 2023, we had $35,220 of pre-valuation allowance tax credit carryforwards of which $26,728 relates to offsets of deferred tax liabilities related to German branches of a U.S. subsidiary. These credit carryforwards can be used through fiscal 2033. We review the need for a valuation allowance against our deferred tax assets. A valuation allowance of $20,315 has been applied to a portion of the net deferred tax assets because we do not believe it is more-likely-than-not that we will receive future benefit. The valuation allowance decreased during fiscal 2023 by $4,376. Other than the tax expense previously recorded for the one-time transition tax on unremitted earnings of non-US subsidiaries, no additional provision has been made for income taxes on undistributed earnings of foreign subsidiaries as the Company’s position is that these amounts continue to be indefinitely reinvested. The amount of undistributed earnings of subsidiaries was approximately $1,915,000 at March 31, 2023. It is not practicable to estimate the additional income taxes and applicable withholding taxes that would be payable on the remittance of such undistributed earnings. On October 8, 2021, the Organization for Economic Co-operation and Development ("OECD") announced the OECD/G20 Inclusive Framework on Base Erosion and Profit Shifting which agreed to a two-pillar solution to address tax challenges arising

Benefit Plans

Benefit Plans	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Benefit Plans	9.BENEFIT PLANS In the United States, we sponsor an unfunded post-retirement welfare benefits plan for two groups of United States retirees. Benefits under this plan include retiree life insurance and retiree medical insurance, including prescription drug coverage. During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years. We sponsor several defined benefit pension schemes outside the United States: two in the UK, one in the Netherlands, two in Germany, and one in Switzerland. The Synergy Health plc Retirement Benefit Scheme is a defined benefit (final salary) funded pension scheme. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long-term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Allershausen Schemes are unfunded defined pension schemes and are closed to new entrants. The Synergy Daniken Scheme is a defined benefit funded pension scheme. As a result of our fiscal 2018 acquisition of Harwell Dosimeters Ltd, we also sponsor the Harwell Dosimeters Ltd Retirement Benefits Scheme which is a defined benefit funded pension scheme. We recognize the funded status of our defined benefit pension and post-retirement benefit plans in our Consolidated Balance Sheets, with a corresponding adjustment to accumulated other comprehensive income, net of tax. The funded status is measured as of March 31 each year and is calculated as the difference between the fair value of plan assets and the benefit obligation (which is the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for post-retirement benefit plans). Accumulated comprehensive income (loss) represents the net unrecognized actuarial losses and unrecognized prior service cost. These amounts will be recognized in net periodic benefit cost as they are amortized. We will recognize future changes to the funded status of these plans in the year the change occurs, through other comprehensive income. Obligations and Funded Status. The following table reconciles the funded status of the defined benefit pension plans and the other post-retirement benefits plan to the amounts recorded on our Consolidated Balance Sheets at March 31, 2023 and 2022, respectively. Benefit obligation balances presented in the following table reflect the projected benefit obligations for our defined benefit pension plans and the accumulated other post-retirement benefit obligation for our post-retirement benefits plan. The measurement date of our defined benefit pension plans and other post-retirement benefits plan is March 31, for both periods presented. Defined Benefit Pension Plans Other 2023 2022 2023 2022 Change in Benefit Obligations: Benefit Obligations at Beginning of Year $ 129,772 $ 149,200 $ 8,525 $ 10,016 Service cost 1,276 1,616 — — Interest cost 3,054 2,820 256 232 Actuarial loss (gain) (27,046) (12,177) (807) (640) Benefits and expenses (5,817) (5,375) (783) (1,083) Employee contributions 501 897 — — Curtailments/settlements (421) (1,334) — — Impact of foreign currency exchange rate changes (7,679) (5,875) — — Benefit Obligations at End of Year 93,640 129,772 7,191 8,525 Change in Plan Assets: Fair Value of Plan Assets at Beginning of Year 142,172 145,452 — — Actual return on plan assets (25,828) 3,421 — — Employer contributions 4,936 5,533 783 1,083 Employee contributions 501 897 — — Benefits and expenses paid (5,772) (5,325) (783) (1,083) Curtailments/settlements (421) (1,334) — — Impact of foreign currency exchange rate changes (8,499) (6,472) — — Fair Value of Plan Assets at End of Year 107,089 142,172 — — Funded Status of the Plans $ 13,449 $ 12,400 $ (7,191) $ (8,525) Amounts recognized in the consolidated balance sheets consist of the following: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2023 2022 2023 2022 Non-current assets $ 16,325 $ 14,172 $ — $ — Current liabilities — — (1,121) (1,190) Non-current liabilities (2,876) (1,772) (6,070) (7,335) Net assets (liabilities) $ 13,449 $ 12,400 $ (7,191) $ (8,525) The pre-tax amount of unrecognized actuarial net loss and unamortized prior service cost included in accumulated other comprehensive (loss) at March 31, 2023, was approximately $750 and $(5,602), respectively. Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2023 and 2022: Defined Benefit Pension Plans 2023 2022 Aggregate fair value of plan assets $ 107,089 $ 142,172 Aggregate accumulated benefit obligations 93,640 129,772 Aggregate projected benefit obligations 93,640 129,772 Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income. Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2023 2022 2021 2023 2022 2021 Service cost $ 1,276 $ 1,616 $ 1,357 $ — $ — $ — Interest cost 3,054 2,699 2,628 256 232 317 Expected return on plan assets (3,817) (4,412) (3,463) — — — Prior service cost recognition 48 61 71 — (267) (3,263) Net amortization and deferral 19 18 21 329 444 439 Curtailments/settlements (49) (31) — — — — Net periodic benefit (credit) cost $ 531 $ (49) $ 614 $ 585 $ 409 $ (2,507) Recognized in other comprehensive loss (income) before tax: Net loss (gain) occurring during year $ 1,716 $ (11,028) $ (1,635) $ 807 $ 640 $ 114 Amortization of prior service credit (263) (222) (85) — 267 3,263 Amortization of net loss — — 7 (329) (444) (439) Total recognized in other comprehensive loss (income) 1,453 (11,250) (1,713) 478 463 2,938 Total recognized in total benefits cost and other comprehensive loss (income) $ 1,984 $ (11,299) $ (1,099) $ 1,063 $ 872 $ 431 Assumptions Used in Calculating Benefit Obligations and Net Periodic Benefit Cost. The following table presents significant assumptions used to determine the projected benefit obligations at March 31: 2023 2022 Discount Rate: Synergy Health plc Retirement Benefits Scheme 4.70 % 2.80 % Isotron BV Pension Plan 3.70 % 1.80 % Synergy Health Daniken AG 2.05 % 0.90 % Synergy Health Radeberg 3.80 % 1.60 % Synergy Health Allershausen 3.70 % 1.50 % Harwell Dosimeters Ltd Retirement Benefits Scheme 4.80 % 2.85 % Other post-retirement plan 4.75 % 3.25 % The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31: 2023 2022 2021 Discount Rate: Synergy Health plc Retirement Benefits Scheme 2.80 % 2.10 % 2.40 % Isotron BV Pension Plan 1.80 % 0.90 % 1.60 % Synergy Health Daniken AG 2.05 % 1.00 % 0.70 % Synergy Health Radeberg 2.00 % 1.50 % 1.50 % Synergy Health Allershausen 2.20 % 2.00 % 1.75 % Harwell Dosimeters Ltd Retirement Benefits Scheme 4.80 % 2.85 % 2.15 % Other post-retirement plan 3.25 % 2.50 % 3.00 % Expected Return on Plan Assets: Synergy Health plc Retirement Benefits Scheme 3.20 % 3.60 % 3.50 % Isotron BV Pension Plan 1.80 % 0.90 % 1.60 % Synergy Health Daniken AG 1.95 % 1.00 % 0.70 % The net periodic benefit cost and the actuarial present value of projected benefit obligations are based upon assumptions that we review on an annual basis. These assumptions may be revised annually based upon an evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing benefits. We develop our expected long-term rate of return on plan assets assumptions by evaluating input from third-party professional advisers, taking into consideration the asset allocation of the portfolios and the long-term asset class return expectations. We develop our discount rate assumptions by evaluating input from third-party professional advisers, taking into consideration the current yield on country specific investment grade long-term bonds which provide for similar cash flow streams as our projected obligations. We have made assumptions regarding healthcare costs in computing our other post-retirement benefit obligation. The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below. 2023 2022 2021 Healthcare cost trend rate – medical 7.50 % 7.00 % 7.00 % Healthcare cost trend rate – prescription drug 7.50 % 7.00 % 7.00 % Long-term healthcare cost trend rate 4.50 % 4.50 % 4.50 % To determine the healthcare cost trend rates, we evaluate a combination of information, including ongoing claims cost monitoring, annual statistical analyses of claims data, reconciliation of forecasted claims against actual claims, review of trend assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior. Plan Assets. The investment policies for our plans are generally established by the local pension plan trustees and seek to maintain the plans' ability to meet liabilities and to comply with local minimum funding requirements. Plan assets are invested in diversified portfolios that provide adequate levels of return at an acceptable level of risk. The investment policies are reviewed at least annually and revised, as d eemed appropriate to ensure that the objectives are being met. At March 31, 2023, the targeted allocation for the plans were approximately 75% equity investments and 25% fixed income investments. Financial instruments included in pension plan assets are categorized into three tiers. These tiers include a fair value hierarchy of three levels, based on the degree of subjectivity inherent in the valuation methodology as follows: Level 1 - Quoted prices for identical assets in active markets. Level 2 - Quoted prices for similar assets in active markets with inputs that are observable, either directly or indirectly. Level 3 - Unobservable prices or inputs in which little or no market data exists. The fair value of our pension benefits plan assets at March 31, 2023 and 2022 by asset category is as follows: Fair Value Measurements at March 31, 2023 (In thousands) Total Quoted Significant Significant Cash $ 338 $ 338 $ — $ — Insured annuities 10,285 — 10,285 — Insurance contracts 5,387 — — 5,387 Common and collective trusts valued at net asset value: Equity security trusts 48,137 — — — Debt security trusts 42,942 — — — Total Plan Assets $ 107,089 $ 338 $ 10,285 $ 5,387 Fair Value Measurements at March 31, 2022 (In thousands) Total Quoted Significant Significant Cash $ 559 $ 559 $ — $ — Insured annuities 14,231 — 14,231 — Insurance contracts 5,383 — — 5,383 Common and collective trusts valued at net asset value: Equity security trusts 66,416 — — — Debt security trusts 55,583 — — — Total Plan Assets $ 142,172 $ 559 $ 14,231 $ 5,383 Collective investment trusts are measured at fair value using the net asset value per share practical expedient. These trusts have not been categorized in the fair value hierarchy and are being presented in the tables above to permit a reconciliation of the fair value hierarchy to the total plan assets. The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2023 due to the following: Insurance contracts Balance at March 31, 2021 $ 5,555 Gains (losses) related to assets still held at year-end (115) Transfers out of Level 3 (210) Foreign currency 153 Balance at March 31, 2022 $ 5,383 Gains (losses) related to assets still held at year-end (157) Transfers out of Level 3 320 Foreign currency (159) Balance at March 31, 2023 $ 5,387 Cash Flows. We contribute amounts to our defined benefit pension plans at least equal to the minimum amounts required by applicable employee benefit laws and local tax laws. We expect to make contributions of approximately $3,955 during fiscal 2024. Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2023, the following benefit payments are expected to be made to plan participants: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2024 $ 6,279 $ 1,121 2025 6,265 1,019 2026 6,458 913 2027 6,663 823 2028 6,845 731 2029 and thereafter 37,315 2,620 The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “Act”) provides a prescription drug benefit for Medicare beneficiaries, a benefit we provide to Medicare eligible retirees covered by our post-retirement benefits plan. We have concluded that the prescription drug benefit provided in our post-retirement benefit plan is considered to be actuarially equivalent to the benefit provided under the Act and thus qualifies for the subsidy under the Act. Benefits are subject to a per capita per month cost cap and any costs above the cap become the responsibility of the retiree. Under the plan, the subsidy is applied to reduce the retiree responsibility. As a result, the expected future subsidy no longer reduces our accumulated post-retirement benefit obligation and net periodic benefit cost. We collected subsidies totaling approximately $477 and $660, during fiscal 2023 and fiscal 2022, respectively, which reduced the retiree responsibility for costs in excess of the caps established in the post-retirement benefit plan. Defined Contribution Plans. We maintain 401(k) defined contribution plans for eligible U.S. employees, a 401(k) defined contribution plan for eligible Puerto Rico employees and similar savings plans for certain employees in Canada, United Kingdom, Ireland, and Finland. We provide a match on a specified portion of an employee’s contribution. The U.S. plan assets are held in trust and invested as directed by the plan participants. The Canadian plan assets are held by insurance companies. The aggregate fair value of the U.S. plan a ssets was $1,170,835 a t March 31, 2023. At March 31, 2023, the U.S. plan held 483,931 STERIS ordinary shares with a fair value of $92,566. We paid dividends of $886, $852, and $839 to the plan and participants on STERIS shares held by the plan for the years ended March 31, 2023, 2022, and 2021, respectively. We contributed approxima tely $36,564 , $38,600, and $29,853, to the defined contribution plans for the years ended March 31, 2023, 2022, and 2021 , respectively.

Contingencies

Contingencies	12 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	10.COMMITMENTS AND CONTINGENCIES We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the risks and uncertainties described under the title "product and service related regulations and claims" in Item 1A. of this Annual Report on Form 10-K. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes” in t his Annual Report on Form 10-K. As of March 31, 2023 and 2022, our commercial commitments totaled $108,370 and $98,675, respectively. Commercial commitments include standby letters of credit, letters of credit required as security under our self-insured risk retention policies, and other potential cash outflows resulting from an event that requires payment by us. Approximately $8,036 and $13,900 of the March 31, 2023 and 2022 totals, respectively, relate to letters of credit required as security under our self-ins ured risk retention policies. As of March 31, 2023, we had minimum purchase commitments with suppliers for raw material purchases totaling $57,221 . As of March 31, 2023, we also had commitments of $194,505 for long term construction contracts. Leases We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less. We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in Property, plant, and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of March 31, 2023 and for the twelve-month period then ended. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease. The components of operating lease expense are as follows: Year Ended Year Ended March 31, 2023 March 31, 2022 Fixed operating lease expense $ 45,249 $ 45,158 Variable operating lease expense 21,486 12,659 Total operating lease expense $ 66,735 $ 57,817 Supplemental cash flow information related to operating leases is as follows: Year Ended Year Ended March 31, 2023 March 31, 2022 Cash paid for amounts included in the measurement of operating lease liabilities $ 45,249 $ 45,144 Right-of-use assets obtained in exchange for operating lease obligations, net $ 53,099 $ 79,241 Maturities of lease liabilities at March 31, 2023 are as follows : March 31, 2024 $ 41,709 2025 33,584 2026 26,129 2027 19,659 2028 and thereafter 120,359 Total operating lease payments 241,440 Less imputed interest 45,986 Total operating lease liabilities $ 195,454 In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2023 foreign currency exchange rates. Supplemental information related to operating leases is as follows: March 31, March 31, 2023 2022 Weighted-average remaining lease term of operating leases 10.3 years 9.6 years Weighted-average discount rate of operating leases 3.3 % 3.4 %

Business Segment Information

Business Segment Information	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Business Segment Information	11.BUSINESS SEGMENT INFORMATION We operate and report our financial information in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include endoscopy accessories and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our Applied Sterilization Technologies ("AST") segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment. Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. We d isclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Certain prior period costs were reallocated from the Healthcare segment to Corporate to conform with current year presentation. The prior period segment operating income measure has been recast for comparability. For the year ended March 31, 2023, revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. Three Customers collectively and consistently account for more than 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for appr oxi mately 47.4% and 45.1% o f our Dental segment revenues for the years ended March 31, 2023 and 2022, respectively. Information regarding our segments is presented in the following tables. Years Ended March 31, 2023 2022 2021 Revenues: Healthcare $ 3,085,131 $ 2,845,467 $ 1,954,055 Applied Sterilization Technologies 914,431 852,972 685,912 Life Sciences 536,704 524,964 467,552 Dental 421,573 361,661 — Total revenues $ 4,957,839 $ 4,585,064 $ 3,107,519 Operating income (loss): Healthcare 706,020 649,704 427,089 Applied Sterilization Technologies 429,020 410,101 310,648 Life Sciences 210,225 216,188 180,796 Dental 89,527 84,441 — Corporate (264,791) (283,665) (219,153) Total operating income before adjustments $ 1,170,001 $ 1,076,769 $ 699,380 Less: Adjustments Amortization of acquired intangible assets (1) 376,822 366,434 83,892 Acquisition and integration related charges (2) 24,196 205,788 35,634 Tax restructuring costs (3) 661 301 1,592 Gain on fair value adjustment of acquisition related contingent consideration (1) (3,100) (2,350) (500) Net (gain) loss on divestiture of businesses (1) (67) (874) 2,030 Amortization of inventory and property "step up" to fair value (1) 12,254 81,804 5,600 COVID-19 incremental costs (4) — — 25,793 Restructuring charges (credit) (5) 485 48 (3,029) Goodwill impairment loss (6) 490,565 — — Total operating income $ 268,185 $ 425,618 $ 548,368 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures." (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. (5) For more information regarding our restructuring efforts, refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021. (6) For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets." Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments. Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together. March 31, 2023 2022 Assets Healthcare and Life Sciences $ 6,538,270 $ 6,604,893 Applied Sterilization Technologies 3,124,341 3,053,116 Dental 1,159,228 1,765,585 Total assets $ 10,821,839 $ 11,423,594 Years Ended March 31, 2023 2022 2021 Capital Expenditures Healthcare and Life Sciences $ 98,585 $ 84,487 $ 74,446 Applied Sterilization Technologies 253,914 198,350 164,816 Dental 9,470 4,726 — Total Capital Expenditures $ 361,969 $ 287,563 $ 239,262 Depreciation, Depletion, and Amortization (1) Healthcare and Life Sciences $ 306,377 $ 316,222 $ 106,266 Applied Sterilization Technologies 116,153 115,925 112,971 Dental 130,367 120,957 — Total Depreciation, Depletion, and Amortization $ 552,897 $ 553,104 $ 219,237 (1) Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures." Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant, and equipment, net are those assets that are identified within the operations in each geographic area. March 31, 2023 2022 Property, Plant, and Equipment, Net Ireland $ 60,570 $ 60,275 United States 946,930 881,057 Other locations 698,012 611,244 Property, Plant, and Equipment, Net $ 1,705,512 $ 1,552,576 Years Ended March 31, 2023 2022 2021 Revenues: Ireland $ 74,463 $ 82,011 $ 71,905 United States 3,586,486 3,228,864 2,227,038 Other locations 1,296,890 1,274,189 808,576 Total Revenues $ 4,957,839 $ 4,585,064 $ 3,107,519 Years Ended March 31, 2023 2022 2021 Healthcare: Capital equipment 896,590 $ 782,505 $ 588,864 Consumables 1,050,316 1,004,605 510,946 Service 1,138,225 1,058,357 854,245 Total Healthcare Revenues $ 3,085,131 $ 2,845,467 $ 1,954,055 Applied Sterilization Technologies: Capital equipment $ 26,460 $ 24,394 $ — Service $ 887,971 $ 828,578 $ 685,912 Total Applied Sterilization Technologies Service Revenues $ 914,431 $ 852,972 $ 685,912 Life Sciences: Capital equipment $ 147,420 $ 142,281 $ 128,356 Consumables 241,114 239,365 215,005 Service 148,170 143,318 124,191 Total Life Sciences Revenues $ 536,704 524,964 467,552 Dental Revenues $ 421,573 $ 361,661 $ — Total Revenues $ 4,957,839 $ 4,585,064 $ 3,107,519

Common Shares

Common Shares	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Earnings Per Share [Text Block]	12.SHARES AND PREFERRED SHARES Ordinary Shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Years ended March 31, 2023 2022 2021 Denominator ( shares in thousands ): Weighted average shares outstanding—basic 99,706 97,535 85,203 Dilutive effect of share equivalents 540 791 695 Weighted average shares outstanding and share equivalents—diluted 100,246 98,326 85,898 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Years ended March 31, 2023 2022 2021 Number of ordinary share options ( shares in thousands ) 578 243 348 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Repurchases of Common Shares

Repurchases of Common Shares	12 Months Ended
	Mar. 31, 2023
Repurchases of Common Shares [Abstract]
Schedule of Treasury Stock by Class [Text Block]	13.REPURCHASES OF ORDINARY SHARES On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of March 31, 2023, there was approximately $13,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations. During fiscal 2023, we repurchased 1,563,983 of our ordinary shares for the aggregate amount of $295,000 (net of fees and commissions) pursuant to the authorizations. From February 14, 2022, through March 31, 2022, we repurchased 108,368 of our ordinary shares for the aggregate amount of $25,000 (net of fees and commissions) pursuant to the authorizations. During fiscal 2021, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During fiscal 2023, we obtained 79,169 of our ordinary shares in the aggregate amount of $13,534 in connection with share-based compensation award programs. During fiscal 2022, we obtained 244,395 of our ordinary shares in the aggregate amount of $30,775 in connection with share-based compensation award programs. During fiscal 2021, we obtained 91,567 of our ordinary shares in the aggregate amount of $9,599 in connection with share-based compensation award programs. On May 3, 2023, our Board of Directors terminated the existing share repurchase program and authorized a new share repurchase program for the purchase of up to $500,000 (net of taxes, fees and commissions). We have not made any repurchases under the new share repurchase program to date.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	14.SHARE-BASED COMPENSATION We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of March 31, 2023, 2,794,795 shares remained available for grant under the long-term incentive plan. The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as Cost of revenues or Selling, general, and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during fiscal 2023, fiscal 2022 and fiscal 2021: Fiscal 2023 Fiscal 2022 Fiscal 2021 Risk-free interest rate 2.44 % 1.10 % 0.46 % Expected life of options 5.9 years 5.9 years 6.0 years Expected dividend yield of stock 0.80 % 0.95 % 0.96 % Expected volatility of stock 24.49 % 24.27 % 23.04 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.54%, 2.85% and 2.78% was applied in fiscal 2023, 2022 and 2021 respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 235,435 247.45 Exercised (37,732) 50.86 Forfeited (8,928) 205.25 Outstanding at March 31, 2023 1,749,729 $ 154.60 6.2 years $ 83,950 Exercisable at March 31, 2023 1,124,664 $ 122.41 5.2 years $ 79,561 We estimate that 614,758 of the non-vested stock options outstanding at March 31, 2023 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $191.28 closing price of our ordinary shares on March 31, 2023 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares. The total intrinsic value of stock options exercised during the years ended March 31, 2023, 2022 and 2021 was $6,502, $52,952 and $39,055, respectively. Net cash proceeds from the exercise of stock options were $1,828, $10,071 and $26,726 for the years ended March 31, 2023, 2022 and 2021, respectively. The tax benefit from stock option exercises w as $4,945 , $18,143 and $11,559 for the years ended March 31, 2023, 2022 and 2021, respectively. The weighted average grant date fair value of stock option grants was $50.72, $37.52 and $27.66 for the years ended March 31, 2023, 2022 and 2021, respectively. A summary of the non-vested restricted share and restricted share unit activity is presented below: Number of Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 131,650 13,884 223.57 Vested (148,828) (16,335) 127.98 Forfeited (17,539) (2,684) 182.75 Non-vested at March 31, 2023 450,793 28,542 $ 186.60 Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during fiscal 2023 was $21,154. As of March 31, 2023, there was a total of $64,814 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.1 years. Cantel Share-Based Compensation Plan In connection with the June 2, 2021 acquisition of Cantel, outstanding, non-vested Cantel restricted share units were replaced with STERIS restricted share units. A total 280,402 STERIS restricted share units replaced Cantel awards based on a ratio of one Cantel restricted share unit to 0.4262 STERIS restricted share units. These Cantel awards consisted of time and performance based awards. Cantel time based restricted share units were replaced with STERIS restricted share units with the same three-year pro-rata vesting terms based on the original award date. Performance based Cantel restricted share units were replaced with time based STERIS restricted share units that vest pro rata over the remaining one, two or three anniversaries from the original Cantel award date. The number of performance restricted share units was replaced based on the original target achievement level. All replacement restricted share units retained dividend accumulation rights. The fair value of each STERIS restricted share unit awarded on June 2, 2021 to replace outstanding non-vested Cantel restricted share units was $191.18 based on the closing price of STERIS ordinary shares on June 2, 2021. Approximately $18,173 of the total $53,607 grant date fair value was attributable to pre-acquisition services provided and was recorded as a component of purchase consideration in connection with the acquisition of Cantel. During fiscal 2022, recognition of unamortized share-based compensation expense totaling $20,200 was accelerated in connection with the termination of certain Cantel employees in fiscal 2022. As a result of the formal notices provided and the terms of the Cantel share-based compensation plans and Cantel Executive Severance and Change of Control Plan, the restricted share units vested requiring acceleration of the remaining related compensation cost. As of March 31, 2023, there was a total of $1,563 in unrecognized compensation cost related to non-vested STERIS restricted share units awarded to replace Cantel restricted share units. We expect to recognize the cost over a weighted average period of 0.6 years. A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 45,722 $ 191.18 Granted — — Vested (25,470) 191.18 Forfeited (4,582) 191.18 Non-vested at March 31, 2023 15,670 $ 191.18

Financial and Other Guarantees

Financial and Other Guarantees	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Product Warranty Disclosure [Text Block]	15.FINANCIAL AND OTHER GUARANTEES We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the periods presented are as follows: Years Ended March 31, 2023 2022 2021 Balance, Beginning of Year $ 14,108 $ 9,406 $ 7,381 Liabilities assumed in acquisition of Cantel — 4,769 — Warranties issued during the period 13,268 12,571 10,574 Settlements made during the period (13,693) (12,638) (8,549) Balance, End of Year $ 13,683 $ 14,108 $ 9,406

Forward and Swap Contracts

Forward and Swap Contracts	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	16.DERIVATIVES AND HEDGING From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including intercompany transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During fiscal 2023, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar-denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts matured during fiscal 2023. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At March 31, 2023, we held foreign currency forward contracts to buy 19.5 million British pounds sterling; and to sell 150.0 million Mexican pesos, and 7.0 million Singapore dollars and 6.0 million euros. At March 31, 2023, we held commodity swap contracts to buy 753.0 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location March 31, 2023 March 31, 2022 March 31, 2023 March 31, 2022 Prepaid & Other $ 378 $ 2,780 $ — $ — Accrued expenses and other — — 2,054 198 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of (loss) gain recognized in income Amount of (loss) gain recognized in income Years Ended March 31, 2023 2022 2021 Foreign currency forward contracts Selling, general, and administrative $ 5,036 $ 4,379 $ 1,178 Commodity swap contracts Cost of revenues (3,630) 3,921 771

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Fair Value Disclosures [Text Block]	17.FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at March 31, 2023 and March 31, 2022: Fair Value Measurements At March 31, Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 2023 2022 2023 2022 2023 2022 2023 2022 Assets: Cash and cash equivalents $ 208,357 $ 348,320 $ 208,357 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 378 2,780 — — 378 2,780 — — Equity investments (2) 7,069 8,520 7,069 8,520 — — — — Other investments 2,066 2,272 2,066 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 2,054 $ 198 $ — $ — $ 2,054 $ 198 $ — $ — Deferred compensation plans (2) 1,022 1,240 1,022 1,240 — — — — Total debt (3) 3,078,655 3,088,356 — — 2,754,218 2,991,680 — — Contingent consideration obligations (4) 15,678 10,550 — — — — 15,678 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statement of Income. During fiscal 2023 and fiscal 2022, we recorded losses of $(1,176) and $(775), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis are summarized as follows: Contingent Consideration Balance at March 31, 2021 $ 19,642 Liabilities assumed in acquisition of Cantel 25,000 Additions 601 Payments (32,336) Reductions and adjustments (2,350) Foreign currency translation adjustments (7) Balance at March 31, 2022 $ 10,550 Additions 8,302 Payments (80) Adjustments (3,100) Foreign currency translation adjustments 6 Balance at March 31, 2023 $ 15,678 Additions and payments of contingent consideration obligations during fiscal year 2023 and 2022 were primarily related to our fiscal year 2023 and 2022 acquisitio ns. Adjustments are recorded in the Selling, general, and administrative expenses line of the Consolidated Statements of Income.
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at March 31, 2023 and March 31, 2022: Fair Value Measurements At March 31, Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 2023 2022 2023 2022 2023 2022 2023 2022 Assets: Cash and cash equivalents $ 208,357 $ 348,320 $ 208,357 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 378 2,780 — — 378 2,780 — — Equity investments (2) 7,069 8,520 7,069 8,520 — — — — Other investments 2,066 2,272 2,066 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 2,054 $ 198 $ — $ — $ 2,054 $ 198 $ — $ — Deferred compensation plans (2) 1,022 1,240 1,022 1,240 — — — — Total debt (3) 3,078,655 3,088,356 — — 2,754,218 2,991,680 — — Contingent consideration obligations (4) 15,678 10,550 — — — — 15,678 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statement of Income. During fiscal 2023 and fiscal 2022, we recorded losses of $(1,176) and $(775), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Reclassifications out of AOCI (

Reclassifications out of AOCI (Notes)	12 Months Ended
	Mar. 31, 2023
Reclassifications out of AOCI Equity [Abstract]
Reclassifications Out of AOCI [Text Block]	18.RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity and changes in our balances, net of tax, for the years ended March 31, 2023, 2022 and 2021 were as follows: Defined Benefit Plans (1) Foreign Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) 2023 2022 2021 2023 2022 2021 2023 2022 2021 Beginning Balance $ 1,276 $ (5,519) $ (6,813) $ (211,084) $ (55,724) $ (228,650) $ (209,808) $ (61,243) $ (235,463) Other Comprehensive (Loss) Income before reclassifications (799) 11,148 4,622 (109,638) (155,360) 172,926 (110,437) (144,212) 177,548 Reclassified from Accumulated Other Comprehensive Loss (465) (4,353) (3,328) — — — (465) (4,353) (3,328) Net current-period Other Comprehensive (Loss) Income (1,264) 6,795 1,294 (109,638) (155,360) 172,926 (110,902) (148,565) 174,220 Ending Balance $ 12 $ 1,276 $ (5,519) $ (320,722) $ (211,084) $ (55,724) $ (320,710) $ (209,808) $ (61,243) (1) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense (income) line of our Consolidated Statements of Income.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Mar. 31, 2023
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS Description Balance at Charges Charges Deductions Balance at (in thousands) Year ended March 31, 2023 Deducted from asset accounts: Allowance for credit losses (1) $ 24,371 $ 6,972 $ 598 (3) $ (8,514) (4) $ 23,427 Inventory valuation reserve 30,937 14,313 (2) 332 (3) — 45,582 Deferred tax asset valuation allowance 24,691 1,733 (530) (3) (5,579) 20,315 Recorded within liabilities: Casualty loss reserves $ 26,126 $ 7,829 $ 2,040 $ (5,558) $ 30,437 Year ended March 31, 2022 Deducted from asset accounts: Allowance for credit losses (1) $ 11,355 $ 16,442 $ 1,840 (3) $ (5,266) (4) $ 24,371 Inventory valuation reserve 19,778 10,931 (2) 228 (3) — 30,937 Deferred tax asset valuation allowance 14,143 2,888 8,906 (3) (1,246) 24,691 Recorded within liabilities: Casualty loss reserves $ 23,283 $ 7,069 $ 44 $ (4,270) $ 26,126 Year ended March 31, 2021 Deducted from asset accounts: Allowance for trade accounts receivable (1) $ 12,051 $ 3,097 $ 349 (3) $ (4,142) (4) $ 11,355 Inventory valuation reserve 16,149 4,423 (2) (794) (3) — 19,778 Deferred tax asset valuation allowance 13,891 2,684 277 (3) (2,709) 14,143 Recorded within liabilities: Casualty loss reserves $ 23,228 $ 5,550 $ 2,542 $ (8,037) $ 23,283 (1) Net allowance for credit losses and allowance for sales and returns. (2) Provision for excess and obsolete inventory, net of inventory written off. (3) Change in foreign currency exchange rates and acquired reserves. (4) Uncollectible accounts written off, net of recoveries.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Property, Plant and Equipment, Impairment [Policy Text Block]	Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition and Associated Liabilities. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At March 31, 2023, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During fiscal 2023, we recognized revenue of $78,752 that was included in our contract liability balance at the beginning of the period. During fiscal 2022, we recognized revenue of $46,760 that was included in our contract liability balance at the beginning of the period. Refer to Note 7 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 7 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of March 31, 2023, the transaction price allocated to remaining performance obligations was approximately $1,553,461 . We expect to recognize approximately 60% of the transaction price within one year and approximately 30% beyond one year. The remainder has yet to be scheduled for delivery.
Consolidation, Policy	Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements.
Use of Estimates, Policy	Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available.
Cash and Cash Equivalents, Policy	Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds, money market deposit accounts, bank savings accounts, and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity.
Trade and Other Accounts Receivable, Policy	Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile. We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience.
Inventory, Policy	Inventories, net. Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead. We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to Cost of revenues.
Property, Plant and Equipment, Policy	Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred. Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method. We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20 When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs.
Investment, Policy	Investments. Investments in marketable securities are stated at fair value and are included in Other assets on the Consolidated Balance Sheets. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statements of Income.
Asset Retirement Obligation [Policy Text Block]	Asset Retirement Obligations. We incur retirement obligations for certain assets. We record initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 titled, “Property, Plant, and Equipment.”
Business Combinations Policy	Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred.
Foreign Currency Transactions and Translations Policy	Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statements of Income, except for certain intercompany balances designated as long-term in nature.
Derivatives, Policy	Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including intercompany transactions.We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our Cost of revenues. We may also hold forward foreign exchange contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within Selling, general, and administrative expenses or Cost of revenues in the accompanying Consolidated Statements of Income.
Standard Product Warranty, Policy	Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience.
Shipping and Handling Cost, Policy	Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized.
Advertising Costs, Policy	Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, general, and administrative expenses. We incurred $21,668, $15,599, and $6,795 of advertising costs during the years ended March 31, 2023, 2022, and 2021, respectively.
Accounting Standards Update and Change in Accounting Principle	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023. ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements. Standards that have not yet been adopted. ASU 2022-04 "Liabilities - Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations September 2022 The standard provides guidance to enhance the transparency of disclosures for entities that utilize supplier finance programs to include information about the key terms of the programs and present a rollforward of any obligations under the program where those obligations are presented in the balance sheet. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
Intangible Assets, Finite-Lived, Policy	Identifiable Intangible Assets.  Our identifiable intangible assets include product technology rights, trademarks, licenses, non-compete agreements, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. Determining the fair value of identifiable intangible requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates, among other items. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment.
Goodwill and Intangible Assets, Goodwill, Policy	Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Management's judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other marketplace participants.
Self Insurance Liabilities, Policy	Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience.
Postemployment Benefit Plans, Policy	Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis. We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 titled, “Benefit Plans.”
Fair Value Measurement, Policy	Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.”
Research and Development Expense, Policy	Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues.
Income Tax, Policy	Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate. We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 titled, “Income Taxes.”
Share-based Compensation, Option and Incentive Plans Policy	Share-Based Compensation.  We describe share-based compensation in Note 14 titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as Cost of revenues, Selling, general, and administrative expenses or Research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statements of Income over the period during which an employee is required to provide service in exchange for the award.
Costs Associated with Exit or Disposal Activity or Restructuring	Restructuring.  We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are re-evaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets.
Interest Expense, Policy	Interest. We capitalize interest costs incurred during the construction of long-lived assets. We capitalized interest costs of $6,366 and $3,886 for the years ended March 31, 2023 and 2022, respectively. Total interest expense for the years ended March 31, 2023, 2022, and 2021 was $107,989, $89,593, and $37,180, respectively.

Contingencies Lease Policy (Pol

Contingencies Lease Policy (Policies)	12 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Lessee, Leases [Policy Text Block]	Leases We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less. We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in Property, plant, and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of March 31, 2023 and for the twelve-month period then ended. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Cash Flow, Supplemental Disclosures	Information supplementing our Consolidated Statements of Cash Flows is as follows: Years Ended March 31, 2023 2022 2021 Cash paid during the year for: Interest $ 108,470 $ 84,696 $ 36,257 Income taxes 254,661 138,382 109,646 Cash received during the year for income tax refunds 2,315 4,605 4,631
Accounting Standards Update and Change in Accounting Principle	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023. ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements. Standards that have not yet been adopted. ASU 2022-04 "Liabilities - Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations September 2022 The standard provides guidance to enhance the transparency of disclosures for entities that utilize supplier finance programs to include information about the key terms of the programs and present a rollforward of any obligations under the program where those obligations are presented in the balance sheet. NA We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
Useful lives of PPE table text block	We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table: Asset Type Useful Life Land improvements 3-40 Buildings and leasehold improvements 2-50 Machinery and equipment 2-20 Information Systems 2-20 Radioisotope (cobalt-60) 20

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Business Combinations and Divestitures [Abstract]
Cantel Acquisition Consideration Paid		The total consideration for Cantel Common Stock and stock equivalents was $3,599,471. The consideration was comprised of the following: (shares in thousands) Cash consideration $16.93 per Cantel share (42,816 shares) $ 716,412 Cash consideration for fractional shares 14 STERIS plc ordinary shares 14,297 shares at ($188.07 per share) 2,689,317 Consideration related to Cantel equity compensation programs 18,173 Consideration related to equity component of Cantel convertible debt 175,555 Total purchase consideration $ 3,599,471
Schedule of Assets Acquired and Liabilities Assumed, Cantel Acquisition	The table below presents the allocation of the purchase price to the net assets acquired based on the fair values at the acquisition date. March 31, 2022 Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant, and equipment 267,360 (1,282) 266,078 Lease right-of-use assets 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471
Schedule of Finite-Lived Intangible Assets		The estimated useful lives are based on the historical experience of STERIS, available similar industry data and assumptions made by management.Values and useful lives are presented in the table below. Total Useful Life Customer relationships $ 2,278,000 9-10 years Trade names 422,000 11 years Developed technology 222,000 9 years Non-compete agreements 20,000 2 years Total intangible assets acquired $ 2,942,000
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information gives effect to our acquisition of Cantel as if the acquisition had occurred on April 1, 2020 and Cantel had been included in our consolidated results of operations for the fiscal years ended March 31, 2022 and 2021. Fiscal Year Ended March 31, (unaudited) 2022 2021 Net revenues $ 4,790,161 $ 4,190,244 Net income from continuing operations 449,382 5,849
Business Combination Assets Acquired and Liabilities Assumed	The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2023, 2022 and 2021 acquisitions. Fiscal Year 2023 (1) Fiscal Year 2022 Fiscal Year 2021 (2) (dollars in thousands) All Acquisitions Other Acquisitions (Excluding Cantel) Key Surgical Other Acquisitions Cash $ — $ — $ 12,615 $ 9,159 Accounts receivable 2,405 — 13,967 9,621 Inventory 12,342 — 21,414 22,123 Property, plant, and equipment 2,131 — 6,030 26,363 Lease right-of-use assets, net 667 — 4,907 4,420 Other assets 177 — 6,680 3,378 Intangible assets (2) 27,576 1,578 356,999 28,188 Goodwill 7,024 1,602 527,675 42,808 Total assets 52,322 3,180 950,287 146,060 Current liabilities (2,007) (34) (21,599) (28,245) Non-current liabilities (473) — (62,870) (9,704) Total liabilities (2,480) (34) (84,469) (37,949) Net assets $ 49,842 $ 3,146 $ 865,818 $ 108,111 (1) Purchase price allocation is still preliminary as of March 31, 2023 for certain acquisitions, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	Changes to the carrying amount of goodwill for the years ended March 31, 2023 and 2022 were as follows: Healthcare Applied Sterilization Technologies Segment Life Sciences Dental Total Balance at March 31, 2021 1,384,763 1,492,239 149,047 — 3,026,049 Cantel goodwill acquired 1,019,332 — 30,356 472,693 1,522,381 Measurement period adjustments to acquired goodwill (6,533) (9,286) — — (15,819) Divestitures (7,000) — — — (7,000) Foreign currency translation adjustments and other (63,732) (50,095) (115) (7,326) (121,268) Balance at March 31, 2022 $ 2,326,830 $ 1,432,858 $ 179,288 $ 465,367 $ 4,404,343 Goodwill acquired 6,221 803 — — 7,024 Measurement period adjustments to acquired goodwill (21,624) — 3,147 40,565 22,088 Impairment — — — (490,565) (490,565) Divestiture (2,358) — — — (2,358) Foreign currency translation adjustments and other (7,796) (37,527) (623) (15,367) (61,313) Balance at March 31, 2023 $ 2,301,273 $ 1,396,134 $ 181,812 $ — $ 3,879,219
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block]	Information regarding our intangible assets is as follows: 2023 2022 March 31, Gross Accumulated Gross Accumulated Customer relationships $ 3,099,544 $ 818,810 $ 3,117,314 $ 539,845 Non-compete agreements 23,486 21,535 23,571 12,392 Patents and technology 534,539 252,809 518,714 211,822 Trademarks and tradenames 468,729 111,158 470,919 74,455 Supplier relationships 54,800 21,006 54,800 18,267 Total $ 4,181,098 $ 1,225,318 $ 4,185,318 $ 856,781
Schedule of Expected Amortization Expense	Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows: 2024 2025 2026 2027 2028 Estimated amortization expense $ 369,358 $ 363,499 $ 354,672 $ 348,506 $ 343,510

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Inventory, Current	Components of our inventories are presented in the following table. March 31, 2023 2022 Raw materials $ 239,081 $ 195,035 Work in process 97,756 76,021 Finished goods 404,238 334,880 Reserve for excess and obsolete inventory (45,582) (30,937) Inventories, net $ 695,493 $ 574,999

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: March 31, 2023 2022 Land and land improvements (1) $ 84,313 $ 84,015 Buildings and leasehold improvements 691,933 654,851 Machinery and equipment 994,188 903,649 Information systems 247,873 222,620 Radioisotope 637,920 597,641 Construction in progress (1) 478,316 356,013 Total property, plant, and equipment 3,134,543 2,818,789 Less: accumulated depreciation and depletion (1,429,031) (1,266,213) Property, plant, and equipment, net $ 1,705,512 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
Schedule of Change in Asset Retirement Obligation [Table Text Block]	The following table summarizes the activity in the liability for asset retirement obligations. Asset Retirement Obligations Balance at March 31, 2021 $ 13,330 Liabilities incurred during the period 86 Liabilities settled during the period (3) Accretion expense and change in estimate 146 Foreign currency and other (16) Balance at March 31, 2022 $ 13,543 Liabilities incurred during the period 86 Liabilities settled during the period (625) Accretion expense and change in estimate 104 Foreign currency and other 23 Balance at March 31, 2023 $ 13,131

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness as of March 31, 2023 and 2022 was as follows: March 31, March 31, Short-term debt Term loan, current portion $ 27,500 $ 27,500 Delayed draw term loan, current portion 32,500 24,375 Private Placement Senior Notes — 91,000 Total short-term debt $ 60,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 750,302 $ 758,726 Revolving Credit Facility 301,672 58,908 Deferred financing costs (21,444) (25,278) Term loan 45,000 177,500 Delayed draw term loan 593,125 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 3,018,655 $ 2,945,481 Total debt $ 3,078,655 $ 3,088,356
Senior Notes in Private Placement [Table Text Block]	Applicable Note Purchase Agreement Maturity Date U.S. Dollar Value at March 31, 2023 U.S. Dollar Value at March 31, 2022 $91,000 Senior notes at 3.20% 2012 Private Placement December 2022 — 91,000 $80,000 Senior notes at 3.35% 2012 Private Placement December 2024 80,000 80,000 $25,000 Senior notes at 3.55% 2012 Private Placement December 2027 25,000 25,000 $125,000 Senior notes at 3.45% 2015 Private Placement May 2025 125,000 125,000 $125,000 Senior notes at 3.55% 2015 Private Placement May 2027 125,000 125,000 $100,000 Senior notes at 3.70% 2015 Private Placement May 2030 100,000 100,000 $50,000 Senior notes at 3.93% 2017 Private Placement February 2027 50,000 50,000 €60,000 Senior notes at 1.86% 2017 Private Placement February 2027 65,254 66,815 $45,000 Senior notes at 4.03% 2017 Private Placement February 2029 45,000 45,000 €20,000 Senior notes at 2.04% 2017 Private Placement February 2029 21,752 22,271 £45,000 Senior notes at 3.04% 2017 Private Placement February 2029 55,579 59,089 €19,000 Senior notes at 2.30% 2017 Private Placement February 2032 20,664 21,158 £30,000 Senior notes at 3.17% 2017 Private Placement February 2032 37,053 39,393 Total Senior Notes $ 750,302 $ 849,726
Schedule of Maturities of Long-term Debt [Table Text Block]	The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows: 2024 $ 60,000 2025 165,938 2026 479,173 2027 614,942 2028 and thereafter 1,780,047 Total $ 3,100,100

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities	Additional information related to our Consolidated Balance Sheets is as follows: March 31, 2023 2022 Accrued payroll and other related liabilities: Compensation and related items $ 48,565 $ 71,878 Accrued vacation/paid time off 11,080 13,669 Accrued bonuses 33,605 64,702 Accrued employee commissions 29,257 30,171 Other post-retirement benefits obligations-current portion 1,121 1,190 Other employee benefit plans' obligations-current portion 2,014 2,111 Total accrued payroll and other related liabilities $ 125,642 $ 183,721 Accrued expenses and other: Deferred revenues $ 92,283 $ 110,791 Service liabilities 72,033 51,365 Self-insured and related risk reserves-current portion 11,325 8,995 Accrued dealer commissions 31,096 31,700 Accrued warranty 13,683 14,108 Asset retirement obligation-current portion 543 1,181 Accrued interest 9,243 10,014 Other 87,611 78,390 Total accrued expenses and other $ 317,817 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 22,171 $ 19,213 Other post-retirement benefits obligations-long-term portion 6,070 7,335 Defined benefit pension plans obligations-long-term portion 2,876 1,772 Other employee benefit plans obligations-long-term portion 1,153 1,360 Accrued long-term income taxes 10,082 12,225 Asset retirement obligation-long-term portion 12,588 12,362 Other 21,197 21,312 Total other liabilities $ 76,137 $ 75,579

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Mar. 31, 2023
Income Tax Expense [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Income from continuing operations before income taxes was as follows: Years Ended March 31, 2023 2022 2021 United States operations $ (16,759) $ 79,662 $ 326,991 Ireland operations 62,664 88,078 73,442 Other locations operations 111,443 146,763 117,100 $ 157,348 $ 314,503 $ 517,533
Schedule of Components of Income Tax Expense (Benefit)	The components of the provision for income taxes related to income from continuing operations consisted of the following: Years Ended March 31, 2023 2022 2021 Current: United States federal $ 138,208 $ 88,158 $ 57,550 United States state and local 33,234 21,438 16,272 Ireland 8,837 12,002 9,244 Other locations 61,446 53,354 36,699 241,725 174,952 119,765 Deferred: United States federal (114,523) (73,833) 7,523 United States state and local (50,530) (17,124) (550) Ireland (864) (739) (787) Other locations (24,273) (11,623) (5,288) (190,190) (103,319) 898 Total Provision for Income Taxes $ 51,535 $ 71,633 $ 120,663
provision for taxes rate reconciliation	The total provision for income taxes can be reconciled to the tax computed at the Ireland statutory tax rate as follows: Years Ended March 31, 2023 2022 2021 National statutory tax rate 12.5 % 12.5 % 12.5 % (Decrease) increase in accruals for uncertain tax positions (0.1) % 0.2 % (0.1) % U.S. state and local taxes, net of federal income tax benefit (10.8) % 1.4 % 2.4 % (Decrease) increase in valuation allowances (0.1) % 0.9 % 0.3 % U.S. research and development credit (1.8) % (0.8) % (0.5) % U.S. foreign income tax credit (1.2) % (1.1) % (0.3) % Difference in non-Ireland tax rates 8.6 % 12.6 % 8.3 % U.S. federal audit adjustments — % — % 2.1 % Impairment of nondeductible goodwill 29.0 % — % — % Excess tax benefit for equity compensation (2.7) % (5.1) % (1.9) % Tax rate changes on deferred tax assets and liabilities 0.4 % 2.3 % 0.4 % U.S. tax reform impact, GILTI and FDII (1.3) % (0.9) % (0.6) % Capitalized acquisition, redomiciliation costs — % 1.8 % 0.6 % All other, net 0.3 % (1.0) % 0.1 % Total Provision for Income Taxes 32.8 % 22.8 % 23.3 %
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible	A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows: 2023 2022 Unrecognized Tax Benefits Balance at April 1 $ 2,906 $ 2,295 Increases for tax provisions of current year 63 — Decreases for tax provisions of prior year — (135) Balances related to acquired/disposed businesses (503) 746 Other, including currency translation 21 — Unrecognized Tax Benefits Balance at March 31 $ 2,487 $ 2,906
Schedule of Deferred Tax Assets and Liabilities	The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2023 and 2022 were as follows: March 31, 2023 2022 Deferred Tax Assets: Post-retirement benefit accrual $ 1,737 $ 2,086 Compensation 15,858 14,340 Net operating loss carryforwards 37,667 25,550 Accrued expenses 13,150 12,092 Insurance 2,268 2,561 Deferred income 23,967 20,688 Bad debt 3,763 2,187 Research & experimental expenditures 15,382 — Operating leases (1) 46,781 44,401 Foreign tax credit carryforwards 33,559 36,036 Other 11,701 8,579 Deferred Tax Assets 205,833 168,520 Less: Valuation allowance 20,315 24,691 Total Deferred Tax Assets 185,518 143,829 Deferred Tax Liabilities: Depreciation and depletion 98,601 110,951 Operating leases (1) 45,834 43,593 Intangibles 630,589 755,980 Pension 2,644 2,004 Other 3,186 3,473 Total Deferred Tax Liabilities 780,854 916,001 Net Deferred Tax Assets (Liabilities) $ (595,336) $ (772,172)

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Defined Benefit Plans Disclosures	Defined Benefit Pension Plans Other 2023 2022 2023 2022 Change in Benefit Obligations: Benefit Obligations at Beginning of Year $ 129,772 $ 149,200 $ 8,525 $ 10,016 Service cost 1,276 1,616 — — Interest cost 3,054 2,820 256 232 Actuarial loss (gain) (27,046) (12,177) (807) (640) Benefits and expenses (5,817) (5,375) (783) (1,083) Employee contributions 501 897 — — Curtailments/settlements (421) (1,334) — — Impact of foreign currency exchange rate changes (7,679) (5,875) — — Benefit Obligations at End of Year 93,640 129,772 7,191 8,525 Change in Plan Assets: Fair Value of Plan Assets at Beginning of Year 142,172 145,452 — — Actual return on plan assets (25,828) 3,421 — — Employer contributions 4,936 5,533 783 1,083 Employee contributions 501 897 — — Benefits and expenses paid (5,772) (5,325) (783) (1,083) Curtailments/settlements (421) (1,334) — — Impact of foreign currency exchange rate changes (8,499) (6,472) — — Fair Value of Plan Assets at End of Year 107,089 142,172 — — Funded Status of the Plans $ 13,449 $ 12,400 $ (7,191) $ (8,525)
Schedule of Accrued Liabilities	Amounts recognized in the consolidated balance sheets consist of the following: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2023 2022 2023 2022 Non-current assets $ 16,325 $ 14,172 $ — $ — Current liabilities — — (1,121) (1,190) Non-current liabilities (2,876) (1,772) (6,070) (7,335) Net assets (liabilities) $ 13,449 $ 12,400 $ (7,191) $ (8,525)
Schedule of Accumulated and Projected Benefit Obligations	Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2023 and 2022: Defined Benefit Pension Plans 2023 2022 Aggregate fair value of plan assets $ 107,089 $ 142,172 Aggregate accumulated benefit obligations 93,640 129,772 Aggregate projected benefit obligations 93,640 129,772
Components of Net Periodic Benefits Cost and Other Amounts Recognized in Other Comprehensive Income [Table Text Block]	Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows: Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2023 2022 2021 2023 2022 2021 Service cost $ 1,276 $ 1,616 $ 1,357 $ — $ — $ — Interest cost 3,054 2,699 2,628 256 232 317 Expected return on plan assets (3,817) (4,412) (3,463) — — — Prior service cost recognition 48 61 71 — (267) (3,263) Net amortization and deferral 19 18 21 329 444 439 Curtailments/settlements (49) (31) — — — — Net periodic benefit (credit) cost $ 531 $ (49) $ 614 $ 585 $ 409 $ (2,507) Recognized in other comprehensive loss (income) before tax: Net loss (gain) occurring during year $ 1,716 $ (11,028) $ (1,635) $ 807 $ 640 $ 114 Amortization of prior service credit (263) (222) (85) — 267 3,263 Amortization of net loss — — 7 (329) (444) (439) Total recognized in other comprehensive loss (income) 1,453 (11,250) (1,713) 478 463 2,938 Total recognized in total benefits cost and other comprehensive loss (income) $ 1,984 $ (11,299) $ (1,099) $ 1,063 $ 872 $ 431
Schedule of Assumptions Used	The following table presents significant assumptions used to determine the projected benefit obligations at March 31: 2023 2022 Discount Rate: Synergy Health plc Retirement Benefits Scheme 4.70 % 2.80 % Isotron BV Pension Plan 3.70 % 1.80 % Synergy Health Daniken AG 2.05 % 0.90 % Synergy Health Radeberg 3.80 % 1.60 % Synergy Health Allershausen 3.70 % 1.50 % Harwell Dosimeters Ltd Retirement Benefits Scheme 4.80 % 2.85 % Other post-retirement plan 4.75 % 3.25 %
Schedule of Net Benefit Costs	The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31: 2023 2022 2021 Discount Rate: Synergy Health plc Retirement Benefits Scheme 2.80 % 2.10 % 2.40 % Isotron BV Pension Plan 1.80 % 0.90 % 1.60 % Synergy Health Daniken AG 2.05 % 1.00 % 0.70 % Synergy Health Radeberg 2.00 % 1.50 % 1.50 % Synergy Health Allershausen 2.20 % 2.00 % 1.75 % Harwell Dosimeters Ltd Retirement Benefits Scheme 4.80 % 2.85 % 2.15 % Other post-retirement plan 3.25 % 2.50 % 3.00 % Expected Return on Plan Assets: Synergy Health plc Retirement Benefits Scheme 3.20 % 3.60 % 3.50 % Isotron BV Pension Plan 1.80 % 0.90 % 1.60 % Synergy Health Daniken AG 1.95 % 1.00 % 0.70 %
Schedule of Health Care Cost Trend Rates	The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below. 2023 2022 2021 Healthcare cost trend rate – medical 7.50 % 7.00 % 7.00 % Healthcare cost trend rate – prescription drug 7.50 % 7.00 % 7.00 % Long-term healthcare cost trend rate 4.50 % 4.50 % 4.50 %
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The fair value of our pension benefits plan assets at March 31, 2023 and 2022 by asset category is as follows: Fair Value Measurements at March 31, 2023 (In thousands) Total Quoted Significant Significant Cash $ 338 $ 338 $ — $ — Insured annuities 10,285 — 10,285 — Insurance contracts 5,387 — — 5,387 Common and collective trusts valued at net asset value: Equity security trusts 48,137 — — — Debt security trusts 42,942 — — — Total Plan Assets $ 107,089 $ 338 $ 10,285 $ 5,387 Fair Value Measurements at March 31, 2022 (In thousands) Total Quoted Significant Significant Cash $ 559 $ 559 $ — $ — Insured annuities 14,231 — 14,231 — Insurance contracts 5,383 — — 5,383 Common and collective trusts valued at net asset value: Equity security trusts 66,416 — — — Debt security trusts 55,583 — — — Total Plan Assets $ 142,172 $ 559 $ 14,231 $ 5,383
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]	The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2023 due to the following: Insurance contracts Balance at March 31, 2021 $ 5,555 Gains (losses) related to assets still held at year-end (115) Transfers out of Level 3 (210) Foreign currency 153 Balance at March 31, 2022 $ 5,383 Gains (losses) related to assets still held at year-end (157) Transfers out of Level 3 320 Foreign currency (159) Balance at March 31, 2023 $ 5,387
Schedule of Expected Benefit Payments	Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2023, the following benefit payments are expected to be made to plan participants: Other Defined Benefit Pension Plans Other Post-Retirement Benefits Plan 2024 $ 6,279 $ 1,121 2025 6,265 1,019 2026 6,458 913 2027 6,663 823 2028 6,845 731 2029 and thereafter 37,315 2,620

Contingencies lease tables (Tab

Contingencies lease tables (Tables)	12 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Lease, Cost	The components of operating lease expense are as follows: Year Ended Year Ended March 31, 2023 March 31, 2022 Fixed operating lease expense $ 45,249 $ 45,158 Variable operating lease expense 21,486 12,659 Total operating lease expense $ 66,735 $ 57,817
Lessee, Supplemental Cash Flow Information	Supplemental cash flow information related to operating leases is as follows: Year Ended Year Ended March 31, 2023 March 31, 2022 Cash paid for amounts included in the measurement of operating lease liabilities $ 45,249 $ 45,144 Right-of-use assets obtained in exchange for operating lease obligations, net $ 53,099 $ 79,241
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of lease liabilities at March 31, 2023 are as follows : March 31, 2024 $ 41,709 2025 33,584 2026 26,129 2027 19,659 2028 and thereafter 120,359 Total operating lease payments 241,440 Less imputed interest 45,986 Total operating lease liabilities $ 195,454 In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2023 foreign currency exchange rates. Supplemental information related to operating leases is as follows: March 31, March 31, 2023 2022 Weighted-average remaining lease term of operating leases 10.3 years 9.6 years Weighted-average discount rate of operating leases 3.3 % 3.4 %

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Segment Reporting Information, by Segment	Years Ended March 31, 2023 2022 2021 Revenues: Healthcare $ 3,085,131 $ 2,845,467 $ 1,954,055 Applied Sterilization Technologies 914,431 852,972 685,912 Life Sciences 536,704 524,964 467,552 Dental 421,573 361,661 — Total revenues $ 4,957,839 $ 4,585,064 $ 3,107,519 Operating income (loss): Healthcare 706,020 649,704 427,089 Applied Sterilization Technologies 429,020 410,101 310,648 Life Sciences 210,225 216,188 180,796 Dental 89,527 84,441 — Corporate (264,791) (283,665) (219,153) Total operating income before adjustments $ 1,170,001 $ 1,076,769 $ 699,380 Less: Adjustments Amortization of acquired intangible assets (1) 376,822 366,434 83,892 Acquisition and integration related charges (2) 24,196 205,788 35,634 Tax restructuring costs (3) 661 301 1,592 Gain on fair value adjustment of acquisition related contingent consideration (1) (3,100) (2,350) (500) Net (gain) loss on divestiture of businesses (1) (67) (874) 2,030 Amortization of inventory and property "step up" to fair value (1) 12,254 81,804 5,600 COVID-19 incremental costs (4) — — 25,793 Restructuring charges (credit) (5) 485 48 (3,029) Goodwill impairment loss (6) 490,565 — — Total operating income $ 268,185 $ 425,618 $ 548,368 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures." (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. (5) For more information regarding our restructuring efforts, refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021. (6) For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets." March 31, 2023 2022 Assets Healthcare and Life Sciences $ 6,538,270 $ 6,604,893 Applied Sterilization Technologies 3,124,341 3,053,116 Dental 1,159,228 1,765,585 Total assets $ 10,821,839 $ 11,423,594 Years Ended March 31, 2023 2022 2021 Capital Expenditures Healthcare and Life Sciences $ 98,585 $ 84,487 $ 74,446 Applied Sterilization Technologies 253,914 198,350 164,816 Dental 9,470 4,726 — Total Capital Expenditures $ 361,969 $ 287,563 $ 239,262 Depreciation, Depletion, and Amortization (1) Healthcare and Life Sciences $ 306,377 $ 316,222 $ 106,266 Applied Sterilization Technologies 116,153 115,925 112,971 Dental 130,367 120,957 — Total Depreciation, Depletion, and Amortization $ 552,897 $ 553,104 $ 219,237 (1) Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area	March 31, 2023 2022 Property, Plant, and Equipment, Net Ireland $ 60,570 $ 60,275 United States 946,930 881,057 Other locations 698,012 611,244 Property, Plant, and Equipment, Net $ 1,705,512 $ 1,552,576
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Years Ended March 31, 2023 2022 2021 Revenues: Ireland $ 74,463 $ 82,011 $ 71,905 United States 3,586,486 3,228,864 2,227,038 Other locations 1,296,890 1,274,189 808,576 Total Revenues $ 4,957,839 $ 4,585,064 $ 3,107,519
Revenue from External Customers by Products and Services [Table Text Block]	Years Ended March 31, 2023 2022 2021 Healthcare: Capital equipment 896,590 $ 782,505 $ 588,864 Consumables 1,050,316 1,004,605 510,946 Service 1,138,225 1,058,357 854,245 Total Healthcare Revenues $ 3,085,131 $ 2,845,467 $ 1,954,055 Applied Sterilization Technologies: Capital equipment $ 26,460 $ 24,394 $ — Service $ 887,971 $ 828,578 $ 685,912 Total Applied Sterilization Technologies Service Revenues $ 914,431 $ 852,972 $ 685,912 Life Sciences: Capital equipment $ 147,420 $ 142,281 $ 128,356 Consumables 241,114 239,365 215,005 Service 148,170 143,318 124,191 Total Life Sciences Revenues $ 536,704 524,964 467,552 Dental Revenues $ 421,573 $ 361,661 $ — Total Revenues $ 4,957,839 $ 4,585,064 $ 3,107,519

Common Shares (Tables)

Common Shares (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Years ended March 31, 2023 2022 2021 Denominator ( shares in thousands ): Weighted average shares outstanding—basic 99,706 97,535 85,203 Dilutive effect of share equivalents 540 791 695 Weighted average shares outstanding and share equivalents—diluted 100,246 98,326 85,898
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Years ended March 31, 2023 2022 2021 Number of ordinary share options ( shares in thousands ) 578 243 348

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during fiscal 2023, fiscal 2022 and fiscal 2021: Fiscal 2023 Fiscal 2022 Fiscal 2021 Risk-free interest rate 2.44 % 1.10 % 0.46 % Expected life of options 5.9 years 5.9 years 6.0 years Expected dividend yield of stock 0.80 % 0.95 % 0.96 % Expected volatility of stock 24.49 % 24.27 % 23.04 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 235,435 247.45 Exercised (37,732) 50.86 Forfeited (8,928) 205.25 Outstanding at March 31, 2023 1,749,729 $ 154.60 6.2 years $ 83,950 Exercisable at March 31, 2023 1,124,664 $ 122.41 5.2 years $ 79,561
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share and restricted share unit activity is presented below: Number of Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 131,650 13,884 223.57 Vested (148,828) (16,335) 127.98 Forfeited (17,539) (2,684) 182.75 Non-vested at March 31, 2023 450,793 28,542 $ 186.60
Share-Based Payment Arrangement, Activity	A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 45,722 $ 191.18 Granted — — Vested (25,470) 191.18 Forfeited (4,582) 191.18 Non-vested at March 31, 2023 15,670 $ 191.18

Financial and Other Guarantees

Financial and Other Guarantees (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Guarantor Obligations	Changes in our warranty liability during the periods presented are as follows: Years Ended March 31, 2023 2022 2021 Balance, Beginning of Year $ 14,108 $ 9,406 $ 7,381 Liabilities assumed in acquisition of Cantel — 4,769 — Warranties issued during the period 13,268 12,571 10,574 Settlements made during the period (13,693) (12,638) (8,549) Balance, End of Year $ 13,683 $ 14,108 $ 9,406

Forward and Swap Contracts (Tab

Forward and Swap Contracts (Tables)	12 Months Ended
	Mar. 31, 2023
Notes To Financial Statements [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location March 31, 2023 March 31, 2022 March 31, 2023 March 31, 2022 Prepaid & Other $ 378 $ 2,780 $ — $ — Accrued expenses and other — — 2,054 198
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of (loss) gain recognized in income Amount of (loss) gain recognized in income Years Ended March 31, 2023 2022 2021 Foreign currency forward contracts Selling, general, and administrative $ 5,036 $ 4,379 $ 1,178 Commodity swap contracts Cost of revenues (3,630) 3,921 771

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at March 31, 2023 and March 31, 2022: Fair Value Measurements At March 31, Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 2023 2022 2023 2022 2023 2022 2023 2022 Assets: Cash and cash equivalents $ 208,357 $ 348,320 $ 208,357 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 378 2,780 — — 378 2,780 — — Equity investments (2) 7,069 8,520 7,069 8,520 — — — — Other investments 2,066 2,272 2,066 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 2,054 $ 198 $ — $ — $ 2,054 $ 198 $ — $ — Deferred compensation plans (2) 1,022 1,240 1,022 1,240 — — — — Total debt (3) 3,078,655 3,088,356 — — 2,754,218 2,991,680 — — Contingent consideration obligations (4) 15,678 10,550 — — — — 15,678 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statement of Income. During fiscal 2023 and fiscal 2022, we recorded losses of $(1,176) and $(775), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, by Balance Sheet Grouping [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis are summarized as follows: Contingent Consideration Balance at March 31, 2021 $ 19,642 Liabilities assumed in acquisition of Cantel 25,000 Additions 601 Payments (32,336) Reductions and adjustments (2,350) Foreign currency translation adjustments (7) Balance at March 31, 2022 $ 10,550 Additions 8,302 Payments (80) Adjustments (3,100) Foreign currency translation adjustments 6 Balance at March 31, 2023 $ 15,678
Fair Value Option, Disclosures	The following table shows the fair value of our financial assets and liabilities at March 31, 2023 and March 31, 2022: Fair Value Measurements At March 31, Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 2023 2022 2023 2022 2023 2022 2023 2022 Assets: Cash and cash equivalents $ 208,357 $ 348,320 $ 208,357 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 378 2,780 — — 378 2,780 — — Equity investments (2) 7,069 8,520 7,069 8,520 — — — — Other investments 2,066 2,272 2,066 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 2,054 $ 198 $ — $ — $ 2,054 $ 198 $ — $ — Deferred compensation plans (2) 1,022 1,240 1,022 1,240 — — — — Total debt (3) 3,078,655 3,088,356 — — 2,754,218 2,991,680 — — Contingent consideration obligations (4) 15,678 10,550 — — — — 15,678 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statement of Income. During fiscal 2023 and fiscal 2022, we recorded losses of $(1,176) and $(775), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Reclassifications out of AOCI_2

Reclassifications out of AOCI (Tables)	12 Months Ended
	Mar. 31, 2023
Reclassifications out of AOCI Equity [Abstract]
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity and changes in our balances, net of tax, for the years ended March 31, 2023, 2022 and 2021 were as follows: Defined Benefit Plans (1) Foreign Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) 2023 2022 2021 2023 2022 2021 2023 2022 2021 Beginning Balance $ 1,276 $ (5,519) $ (6,813) $ (211,084) $ (55,724) $ (228,650) $ (209,808) $ (61,243) $ (235,463) Other Comprehensive (Loss) Income before reclassifications (799) 11,148 4,622 (109,638) (155,360) 172,926 (110,437) (144,212) 177,548 Reclassified from Accumulated Other Comprehensive Loss (465) (4,353) (3,328) — — — (465) (4,353) (3,328) Net current-period Other Comprehensive (Loss) Income (1,264) 6,795 1,294 (109,638) (155,360) 172,926 (110,902) (148,565) 174,220 Ending Balance $ 12 $ 1,276 $ (5,519) $ (320,722) $ (211,084) $ (55,724) $ (320,710) $ (209,808) $ (61,243) (1) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense (income) line of our Consolidated Statements of Income.

Nature of Operations and Summ_4

Nature of Operations and Summary of Siginificant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Loss Contingencies [Line Items]
Deferred Revenue, Revenue Recognized	$ 78,752	$ 46,760
Interest Costs, Capitalized During Period	6,366	3,886
Interest Costs Incurred	107,989	89,593	$ 37,180
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	108,470	84,696	36,257
Income Taxes Paid, Net	254,661	138,382	109,646
Advertising Expense	21,668	15,599	6,795
Proceeds from Income Tax Refunds	2,315	4,605	4,631
Revenue, Remaining Performance Obligation, Amount	1,553,461
Cost of Goods and Services Sold	2,798,147	2,568,702	1,764,419
Gross Profit	2,159,692	2,016,362	1,343,100
Operating Income (Loss)	268,185	425,618	548,368
Income Tax Expense (Benefit)	51,535	71,633	120,663
Net income	105,813	242,870	396,870
Net Income (Loss) Attributable to Parent	$ 107,030	$ 243,888	$ 397,400
Earnings Per Share, Basic	$ 1.07	$ 2.50	$ 4.66
Earnings Per Share, Diluted	$ 1.07	$ 2.48	$ 4.63
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (3,872)	$ 95,323	$ 571,620
Inventory, Net	695,493	574,999
Retained earnings	1,911,533	1,999,244
Increase (Decrease) in Inventories	123,921	102,922	(3,769)
Accruals and other, net	(22,054)	(16,398)	9,916
Deferred income taxes	(185,913)	(106,620)	4,240
Product [Member]
Loss Contingencies [Line Items]
Cost of Goods and Services Sold	$ 1,513,970	$ 1,419,925	$ 765,076
Property, Plant and Equipment, Other Types [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Minimum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5 years
Minimum [Member] | Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] | Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Minimum [Member] | Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Minimum [Member] | Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Maximum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	20 years
Maximum [Member] | Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Maximum [Member] | Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	50 years
Maximum [Member] | Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Maximum [Member] | Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Expected recognition within the next year [Member]
Loss Contingencies [Line Items]
Revenue, Remaining Performance Obligation, Percentage	60%
Expected recognition beyond the next year [Member] [Member]
Loss Contingencies [Line Items]
Revenue, Remaining Performance Obligation, Percentage	30%

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting Policies - Change in Accounting Principle (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Loss Contingencies [Line Items]
Cost of Goods and Services Sold	$ 2,798,147	$ 2,568,702	$ 1,764,419
Gross Profit	2,159,692	2,016,362	1,343,100
Operating Income (Loss)	268,185	425,618	548,368
Income Tax Expense (Benefit)	51,535	71,633	120,663
Net income	105,813	242,870	396,870
Net Income (Loss) Attributable to Parent	$ 107,030	$ 243,888	$ 397,400
Earnings Per Share, Basic	$ 1.07	$ 2.50	$ 4.66
Earnings Per Share, Diluted	$ 1.07	$ 2.48	$ 4.63
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (3,872)	$ 95,323	$ 571,620
Inventory, Net	695,493	574,999
Retained earnings	1,911,533	1,999,244
Increase (Decrease) in Inventories	(123,921)	(102,922)	3,769
Accruals and other, net	(22,054)	(16,398)	9,916
Deferred income taxes	(185,913)	(106,620)	4,240
Product [Member]
Loss Contingencies [Line Items]
Cost of Goods and Services Sold	$ 1,513,970	$ 1,419,925	$ 765,076

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Business Acquisitions and Divestitures Narrative (Details) $ in Thousands				12 Months Ended
		Jan. 03, 2022 USD ($)	Jan. 04, 2021 USD ($)	Mar. 31, 2023 USD ($)		Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jun. 02, 2021 USD ($)
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability				$ 15,678		$ 10,550	$ 19,642
Revenues				4,957,839		4,585,064	3,107,519
Business Combination, Acquisition Related Costs	[1]			24,196		205,788	35,634
Proceeds from Divestiture of Businesses				6,624		169,712	518
Gain (Loss) on Disposition of Business	[2]			(67)		(874)	2,030
Payments to Acquire Businesses, Net of Cash Acquired				42,572		550,449	909,192
Deferred consideration						50	1,194
Business Acquisition, Goodwill, Expected Tax Deductible Amount				$ 4,863		$ 427,035	197,344
Entity Number of Employees						3,700
Cantel Acquisition Assumed Debt Obligations						$ 721,284
Contingent Consideration Liability Assumed in Cantel Combination						25,000		$ 25,000
Business Acquisition, Pro Forma Revenue						4,790,161	4,190,244
Business Acquisition, Pro Forma Net Income (Loss)						449,382	5,849
Net sales attributable to Cantel						974,408
Operating (loss) income attributable to Cantel						$ 41,757
Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				5 years
Minimum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						9 years
Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life				20 years
Maximum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						10 years
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			$ 78,045			$ 3,146	20,909
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				$ 49,842	[3]	3,146	108,111
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				2,131	[3]	0	26,363
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				27,576	[3]	1,578	28,188
Key Surgical [Domain]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired							853,203
Equity Investments [Domain]
Business Acquisition [Line Items]
Non cash consideration paid in acquisition							41,771
Cantel Medical Corp.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						3,599,471
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				266,078		267,360
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill				2,942,000		2,942,000
Cantel Medical Corp. | Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						2,278,000
Cantel Medical Corp. | Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						$ 422,000
Finite-Lived Intangible Asset, Useful Life						11 years
Cantel Medical Corp. | Developed Technology Rights
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						$ 222,000
Finite-Lived Intangible Asset, Useful Life						9 years
Cantel Medical Corp. | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						$ 20,000
Finite-Lived Intangible Asset, Useful Life						2 years
Ohter FY 23 Acquisition
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability				7,269
Payments to Acquire Business Three, Net of Cash Acquired				49,842
AST Lab Divestiture [Domain]
Business Acquisition [Line Items]
Revenues							6,000
Proceeds from Divestiture of Businesses							518
Gain (Loss) on Disposition of Business							$ 2,024
Renal Care
Business Acquisition [Line Items]
Revenues		$ 180,000
Proceeds from Divestiture of Businesses		196,000		1,396
Gain (Loss) on Disposition of Business		4,919
Potential Earnout on Divestiture of Business		$ 12,300
Animal Health Divestiture
Business Acquisition [Line Items]
Revenues				12,000
Proceeds from Divestiture of Businesses				5,228
Gain (Loss) on Disposition of Business				$ (4,852)
[1]Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.[2]For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."[3]1) Purchase price allocation is still preliminary as of March 31, 2023 for certain acquisitions, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.

Business Acquisitions and Div_4

Business Acquisitions and Divestitures Synergy Consideration (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended	12 Months Ended
	Jun. 02, 2021	Jan. 04, 2021	Mar. 31, 2022	Mar. 31, 2023		Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 42,572		$ 550,449	$ 909,192
Consideration related to equity component of convertible debt						175,555
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Cash				0
Operating Lease, Right-of-Use Asset			$ 188,480	191,741		188,480
Goodwill			4,404,343	3,879,219		4,404,343	3,026,049
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Accounts Receivable				0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory				0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Lease right-of-use assets, net				0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Assets				0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				0
Goodwill, Purchase Accounting Adjustments				22,088		(15,819)
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Convertible debt, par value				0
Business Combination Provisional Information Initial Accounting Incomplete ,Adjustment ,Long-term lease obligations				0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Long-term indebtedness				0
Business Combination Provisional Information Initial Accounting Incomplete Adjustment Net Assets Acquired				0
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 78,045				3,146	20,909
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			0	0	[1]	0	9,159
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			0	2,405	[1]	0	9,621
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			0	12,342	[1]	0	22,123
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			0	2,131	[1]	0	26,363
Operating Lease, Right-of-Use Asset			0	667	[1]	0	4,420
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			0	177	[1]	0	3,378
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			1,578	27,576	[1]	1,578	28,188
Goodwill			1,602	7,024	[1]	1,602	42,808
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			3,180	52,322	[1]	3,180	146,060
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			34	2,007	[1]	34	28,245
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			34	2,480	[1]	34	37,949
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			3,146	49,842	[1]	3,146	$ 108,111
Cantel Medical Corp.
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross						716,412
Business Combination, Consideration Transferred, Other						14
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable						2,689,317
Consideration Transferred, Equity Awards Issued and Issuable						18,173
Consideration related to equity component of convertible debt						175,555
Business Combination, Consideration Transferred						3,599,471
Business Combination, Long-term Obligations Assumed			$ 721,284	721,284		$ 721,284
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	42,816		14,297
Business Acquisition, Share Price	$ 16.93		$ 188,070			$ 188,070
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			$ 169,073	169,073		$ 169,073
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			172,226	172,226		172,226
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			249,221	249,221		249,221
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			267,360	266,078		267,360
Operating Lease, Right-of-Use Asset			59,720	59,720		59,720
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			72,864	72,864		72,864
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			2,942,000	2,942,000		2,942,000
Goodwill			1,522,381	1,544,469		1,522,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			5,454,845	5,475,651		5,454,845
Business combination, Convertible Debt, Par Value Assumed			168,000	168,000		168,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			247,549	253,144		247,549
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation			47,856	47,856		47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities			670,685	685,896		670,685
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			1,855,374	1,876,180		1,855,374
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 3,599,471			$ 3,599,471
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment				(1,282)
Goodwill, Purchase Accounting Adjustments				22,088
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets				20,806
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Current Liabilities				5,595
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Deferred Income Taxes				15,211
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities				$ 20,806
[1]1) Purchase price allocation is still preliminary as of March 31, 2023 for certain acquisitions, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.

Business Acquisitions and Div_5

Business Acquisitions and Divestitures Synergy Acquisition (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Operating Lease, Right-of-Use Asset	$ 191,741	$ 188,480
Goodwill	3,879,219	4,404,343	$ 3,026,049
Cantel Medical Corp.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	169,073	169,073
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	172,226	172,226
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	249,221	249,221
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	266,078	267,360
Operating Lease, Right-of-Use Asset	59,720	59,720
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	72,864	72,864
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,942,000	2,942,000
Goodwill	1,544,469	1,522,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	5,475,651	5,454,845
Business combination, Convertible Debt, Par Value Assumed	168,000	168,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(253,144)	(247,549)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(1,876,180)	(1,855,374)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		3,599,471
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	47,856	47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	$ 685,896	$ 670,685

Business Acquisitions and Div_6

Business Acquisitions and Divestitures Synergy Finite-Lived Intangibles (Details) - Cantel Medical Corp. - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 2,942,000	$ 2,942,000
Developed Technology Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 222,000
Finite-Lived Intangible Asset, Useful Life		9 years
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 20,000
Finite-Lived Intangible Asset, Useful Life		2 years

Business Acquisitions and Div_7

Business Acquisitions and Divestitures Business Acquisition Summary (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023		Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses		$ 6,624		$ 169,712	$ 518
Business Combination, Acquisition Related Costs	[1]	24,196		205,788	35,634
Gain (Loss) on Disposition of Business	[2]	67		874	(2,030)
Operating Lease, Right-of-Use Asset		191,741		188,480
Goodwill		3,879,219		4,404,343	3,026,049
Business Acquisition, Goodwill, Expected Tax Deductible Amount		4,863		427,035	197,344
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents		0	[3]	0	9,159
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables		2,405	[3]	0	9,621
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory		12,342	[3]	0	22,123
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		2,131	[3]	0	26,363
Operating Lease, Right-of-Use Asset		667	[3]	0	4,420
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other		177	[3]	0	3,378
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		27,576	[3]	1,578	28,188
Goodwill		7,024	[3]	1,602	42,808
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets		52,322	[3]	3,180	146,060
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities		(2,007)	[3]	(34)	(28,245)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities		(473)	[3]	0	(9,704)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(2,480)	[3]	(34)	(37,949)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		$ 49,842	[3]	$ 3,146	108,111
Key Surgical
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents					12,615
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables					13,967
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory					21,414
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					6,030
Operating Lease, Right-of-Use Asset					4,907
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other					6,680
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[4]				356,999
Goodwill					527,675
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets					950,287
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities					(21,599)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities					(62,870)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					(84,469)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					865,818
Finite-Lived Customer Relationships, Gross					$ 315,575
[1]Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.[2]For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."[3]1) Purchase price allocation is still preliminary as of March 31, 2023 for certain acquisitions, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.[4]The Fiscal 2021 amount includes $315,575, related to the fair value of the Customer relationships intangible asset obtained in the acquisition of Key Surgical. The estimation of fair value was determined under an income approach using discounted cash flows. The estimate requires assumptions including forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates.

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets Narrative (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)		$ 14,250	$ 14,250
Goodwill		3,879,219	4,404,343	$ 3,026,049
Goodwill, Acquired During Period		7,024	1,522,381
Finite-Lived Intangible Assets, Amortization Expense		379,752	368,698	86,512
Finite-Lived Intangible Assets, Gross		4,181,098	4,185,318
Finite-Lived Intangible Assets, Accumulated Amortization		1,225,318	856,781
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Goodwill, Impairment Loss	[1]	490,565	0	$ 0
Trademarks and Trade Names [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross		468,729	470,919
Finite-Lived Intangible Assets, Accumulated Amortization		$ 111,158	$ 74,455
[1]For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets Goodwill Rollforward (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Goodwill [Line Items]
Goodwill		$ 3,879,219	$ 4,404,343	$ 3,026,049
Goodwill, Purchase Accounting Adjustments		22,088	(15,819)
Goodwill, Impairment Loss	[1]	(490,565)	0	0
Goodwill, Acquired During Period		7,024	1,522,381
Goodwill, Written off Related to Sale of Business Unit		(2,358)
Goodwill Decrease from Divestitures			(7,000)
Goodwill, Foreign Currency Translation Gain (Loss)		(61,313)	(121,268)
Healthcare [Member]
Goodwill [Line Items]
Goodwill		2,301,273	2,326,830	1,384,763
Goodwill, Purchase Accounting Adjustments		(21,624)	(6,533)
Goodwill, Impairment Loss		0
Goodwill, Acquired During Period		6,221	1,019,332
Goodwill, Written off Related to Sale of Business Unit		(2,358)
Goodwill Decrease from Divestitures			(7,000)
Goodwill, Foreign Currency Translation Gain (Loss)		(7,796)	(63,732)
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill		1,396,134	1,432,858	1,492,239
Goodwill, Purchase Accounting Adjustments		0	(9,286)
Goodwill, Impairment Loss		0
Goodwill, Acquired During Period		803	0
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill Decrease from Divestitures			0
Goodwill, Foreign Currency Translation Gain (Loss)		(37,527)	(50,095)
Life Sciences
Goodwill [Line Items]
Goodwill		181,812	179,288	149,047
Goodwill, Purchase Accounting Adjustments		3,147	0
Goodwill, Impairment Loss		0
Goodwill, Acquired During Period		0	30,356
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill Decrease from Divestitures			0
Goodwill, Foreign Currency Translation Gain (Loss)		(623)	(115)
Dental
Goodwill [Line Items]
Goodwill		0	465,367	$ 0
Goodwill, Purchase Accounting Adjustments		40,565	0
Goodwill, Impairment Loss		(490,565)
Goodwill, Acquired During Period		0	472,693
Goodwill, Written off Related to Sale of Business Unit		0
Goodwill Decrease from Divestitures			0
Goodwill, Foreign Currency Translation Gain (Loss)		$ (15,367)	$ (7,326)
[1]For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 4,181,098	$ 4,185,318
Finite-Lived Intangible Assets, Accumulated Amortization	1,225,318	856,781
Indefinite-lived Intangible Assets (Excluding Goodwill)	14,250	14,250
Customer Relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,099,544	3,117,314
Finite-Lived Intangible Assets, Accumulated Amortization	818,810	539,845
Noncompete Agreements [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	23,486	23,571
Finite-Lived Intangible Assets, Accumulated Amortization	21,535	12,392
Patented Technology [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	534,539	518,714
Finite-Lived Intangible Assets, Accumulated Amortization	252,809	211,822
Trademarks and Trade Names [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	468,729	470,919
Finite-Lived Intangible Assets, Accumulated Amortization	111,158	74,455
supplier relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	54,800	54,800
Finite-Lived Intangible Assets, Accumulated Amortization	$ 21,006	$ 18,267

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets Future Amortization of Intangible Assets (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Other Intangible Assets [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 369,358
Finite-Lived Intangible Assets, Amortization Expense, Year Two	363,499
Finite-Lived Intangible Assets, Amortization Expense, Year Three	354,672
Finite-Lived Intangible Assets, Amortization Expense, Year Four	348,506
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 343,510

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Notes To Financial Statements [Abstract]
Inventory, Raw Materials	$ 239,081	$ 195,035
Inventory, Work in Process	97,756	76,021
Inventory, Finished Goods	404,238	334,880
Inventory Valuation Reserves	(45,582)	(30,937)
Inventories, net	$ 695,493	$ 574,999

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Document Period End Date		Mar. 31, 2023
Asset Retirement Obligation		$ 13,131	$ 13,543	$ 13,330
Asset Retirement Obligation, Liabilities Incurred		86	86
Asset Retirement Obligation, Liabilities Settled		(625)	(3)
Asset Retirement Obligation, Accretion Expense		104	146
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)		23	(16)
Land	[1]	84,313	84,015
Buildings and Improvements, Gross		691,933	654,851
Machinery and Equipment, Gross		994,188	903,649
Capitalized Computer Software, Gross		247,873	222,620
Materials, Supplies, and Other		637,920	597,641
Construction in Progress, Gross	[1]	478,316	356,013
Property, Plant and Equipment, Gross		3,134,543	2,818,789
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		(1,429,031)	(1,266,213)
Property, Plant and Equipment, Net		1,705,512	1,552,576
Depreciation		$ 173,145	$ 184,406	$ 132,725
[1]Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Details)

Debt (Details) $ / shares in Units, € in Thousands, £ in Thousands			12 Months Ended
	May 15, 2020 USD ($) $ / shares	May 15, 2015 USD ($)	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($) $ / shares	Mar. 31, 2020	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 GBP (£)	Jun. 30, 2022 USD ($)	Jun. 02, 2021 $ / shares shares	Apr. 01, 2021 USD ($)	Mar. 19, 2021 USD ($)	Feb. 27, 2017 USD ($)	Feb. 27, 2017 EUR (€)	Feb. 27, 2017 GBP (£)	Dec. 31, 2012 USD ($)
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			$ 60,000,000
Line of Credit Facility, Amount Outstanding			301,672,000	$ 58,908,000
Long-term Debt			3,100,100,000
Long-term Debt			3,018,655,000	2,945,481,000
Long-term Debt, Maturities, Repayments of Principal in Year Two			165,938,000
Long-term Debt, Maturities, Repayments of Principal in Year Three			479,173,000
Long-term Debt, Maturities, Repayments of Principal in Year Four			614,942,000
Long-term Debt, Maturities, Repayments of Principal after Year Five			1,780,047,000
Term loan, current portion			27,500,000	27,500,000
Delayed draw term loan, current portion			32,500,000	24,375,000
Short-term Debt			60,000,000	142,875,000
Debt Issuance Costs, Net			(21,444,000)	(25,278,000)
Term Loan, long term portion			45,000,000	177,500,000
Delayed Draw Term Loan, long term portion			593,125,000	625,625,000				$ 650,000,000
Debt, Long-Term and Short-Term, Combined Amount			$ 3,078,655,000	3,088,356,000
Business Acquisition, Shares Received Per Ordinary Share | shares									0.33787
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.001						$ 0.001
Debt Instrument, Convertible, Units of Property Reference									25.0843
Debt Instrument, Convertible, Parent Shares | shares									8.4752
Debt Instrument, Convertible, Cash Per One Thousand Dollars Ratio									424.68
Debt Instrument, Convertible, Increase in Conversion Rate, Shares | shares									0.9931
Debt Instrument, Convertible, Stock Price | $ / shares									$ 81.3520
Consideration related to equity component of convertible debt				175,555,000
Convertible debt premium liability			$ 203,361,000
Private Placement
Debt Instrument [Line Items]
Senior Notes, Current			0	$ 91,000,000
Cantel Medical Corp.
Debt Instrument [Line Items]
Business Acquisition, Share Price | $ / shares				$ 188,070					$ 16.93
Consideration related to equity component of convertible debt				$ 175,555,000
10 year maturity
Debt Instrument [Line Items]
Debt Instrument, Term		10 years			10 years
15 year maturity
Debt Instrument [Line Items]
Debt Instrument, Term		15 years
Debt Instrument, Maturity Date, Description					15 years
Senior Notes
Debt Instrument [Line Items]
Senior Notes		$ 350,000,000													$ 200,000,000
Long-term Debt			750,302,000	849,726,000
Debt Instrument, Face Amount										$ 1,350,000,000
Long-term Debt, Cash Settlement Value				371,361,000
Senior Notes, Noncurrent			$ 1,350,000,000	1,350,000,000
Convertible Debt
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 168,000,000
STE 3.70% due 2022 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.20%			3.20%	3.20%
Debt Instrument, Face Amount			$ 0	91,000,000
Debt Instrument, Issued, Principal			$ 91,000,000
STE 3.85% due 2024 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.35%			3.35%	3.35%
Debt Instrument, Face Amount			$ 80,000,000	80,000,000
STE 4.05% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.55%			3.55%	3.55%
Debt Instrument, Face Amount			$ 25,000,000	25,000,000
STE 3.45% due 2025 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.45%			3.45%	3.45%
Debt Instrument, Face Amount			$ 125,000,000	125,000,000
STE 3.55% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.55%			3.55%	3.55%
Debt Instrument, Face Amount			$ 125,000,000	125,000,000
STE 3.70% due 2030 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.70%			3.70%	3.70%
Debt Instrument, Face Amount			$ 100,000,000	100,000,000
STE 3.93% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.93%			3.93%	3.93%
Debt Instrument, Face Amount			$ 50,000,000	50,000,000
STE 1.86% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			1.86%			1.86%	1.86%
Debt Instrument, Face Amount			$ 65,254,000	66,815,000		€ 60,000
STE 4.03% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.03%			4.03%	4.03%
Debt Instrument, Face Amount			$ 45,000,000	45,000,000
STE 2.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.04%			2.04%	2.04%
Debt Instrument, Face Amount			$ 21,752,000	22,271,000		€ 20,000
STE 3.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.04%			3.04%	3.04%
Debt Instrument, Face Amount			$ 55,579,000	59,089,000			£ 45,000
STE 2.30% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.30%			2.30%	2.30%
Debt Instrument, Face Amount			$ 20,664,000	21,158,000		€ 19,000
STE 3.17% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.17%			3.17%	3.17%
Debt Instrument, Face Amount			$ 37,053,000	39,393,000			£ 30,000
Private Placement
Debt Instrument [Line Items]
Senior Notes, Noncurrent			$ 750,302,000	$ 758,726,000
United States of America, Dollars
Debt Instrument [Line Items]
Senior Notes												$ 95,000,000
United Kingdom, Pounds
Debt Instrument [Line Items]
Senior Notes | £														£ 75,000
Euro Member Countries, Euro
Debt Instrument [Line Items]
Senior Notes | €													€ 99,000
2031 Notes | Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										2.70%
Debt Instrument, Face Amount										$ 675,000,000
2051 Notes | Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage										3.75%
Debt Instrument, Face Amount										$ 675,000,000
Cantel Convertible Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.25%
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 41.51
Debt Instrument, Convertible, Conversion Ratio	24.0912
Term Loan Facility | Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 550,000,000
Debt Instrument, Interest Rate, Stated Percentage			1.875%			1.875%	1.875%				1.25%
Revolving Credit Facility [Member] | Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 1,250,000,000
Bridge Loan | Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											625,000,000
Delayed Draw Term Loan | Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 750,000,000
Debt Instrument, Interest Rate, Stated Percentage			1.875%			1.875%	1.875%				1.25%

Debt 2017 Senior Notes (Details

Debt 2017 Senior Notes (Details) € in Thousands, £ in Thousands	Mar. 31, 2023 USD ($)	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 GBP (£)	Mar. 31, 2022 USD ($)	Apr. 01, 2021 USD ($)
Debt Instrument [Line Items]
Long-term Debt	$ 3,018,655,000			$ 2,945,481,000
Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 1,350,000,000
Long-term Debt	750,302,000			849,726,000
STE 3.70% due 2022 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 0			91,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.20%	3.20%	3.20%
STE 3.85% due 2024 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 80,000,000			80,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.35%	3.35%	3.35%
STE 4.05% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 25,000,000			25,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.55%	3.55%	3.55%
STE 3.45% due 2025 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000			125,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.45%	3.45%	3.45%
STE 3.55% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000			125,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.55%	3.55%	3.55%
STE 3.70% due 2030 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 100,000,000			100,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.70%	3.70%	3.70%
STE 3.93% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 50,000,000			50,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.93%	3.93%	3.93%
STE 1.86% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 65,254,000	€ 60,000		66,815,000
Debt Instrument, Interest Rate, Stated Percentage	1.86%	1.86%	1.86%
STE 4.03% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 45,000,000			45,000,000
Debt Instrument, Interest Rate, Stated Percentage	4.03%	4.03%	4.03%
STE 2.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 21,752,000	€ 20,000		22,271,000
Debt Instrument, Interest Rate, Stated Percentage	2.04%	2.04%	2.04%
STE 3.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 55,579,000		£ 45,000	59,089,000
Debt Instrument, Interest Rate, Stated Percentage	3.04%	3.04%	3.04%
STE 2.30% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 20,664,000	€ 19,000		21,158,000
Debt Instrument, Interest Rate, Stated Percentage	2.30%	2.30%	2.30%
STE 3.17% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 37,053,000		£ 30,000	$ 39,393,000
Debt Instrument, Interest Rate, Stated Percentage	3.17%	3.17%	3.17%

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Notes To Financial Statements [Abstract]
Employee-related Liabilities	$ 48,565	$ 71,878
Accrued Vacation	11,080	13,669
Accrued Bonuses	33,605	64,702
Accrued Liabilities for Commissions, Expense and Taxes	29,257	30,171
Liability, Other Retirement Benefits	1,121	1,190
Liability, Retirement and Postemployment Benefits	2,014	2,111
Employee-related Liabilities, Current	125,642	183,721
Deferred Revenue	92,283	110,791
Service liabilities	72,033	51,365
Self Insurance Reserve, Current	11,325	8,995
Accrued Sales Commission	31,096	31,700
Standard and Extended Product Warranty Accrual	13,683	14,108	$ 9,406	$ 7,381
Asset Retirement Obligation, Current	543	1,181
Other Accrued Liabilities	87,611	78,390
Accrued Liabilities	317,817	306,544
Self Insurance Reserve, Noncurrent	22,171	19,213
Liability, Other Retirement Benefits, Noncurrent	6,070	7,335
Liability, Defined Benefit Pension Plan, Noncurrent	2,876	1,772
Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent	1,153	1,360
Accrued Income Taxes, Noncurrent	10,082	12,225
Asset Retirement Obligations, Noncurrent	12,588	12,362
Other Liabilities	21,197	21,312
Other Liabilities, Noncurrent	76,137	75,579
Accrued interest	$ 9,243	$ 10,014

Income Tax Expense (Details)

Income Tax Expense (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	May 21, 2021
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued	$ 152	$ 152
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2,640
Uncertain Tax Liability Resulting From IRS Notice	12,000			$ 50,000
Deferred Tax Assets, Tax Credit Carryforwards	35,220
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits	$ 1,737	$ 2,086
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	12.50%	12.50%	12.50%
Current Federal Tax Expense (Benefit)	$ 8,837	$ 12,002	$ 9,244
Effective Income Tax Rate, Continuing Operations	32.80%	22.80%	23.30%
Unrecognized Tax Benefits	$ 2,487	$ 2,906	$ 2,295
Current State and Local Tax Expense (Benefit)	33,234	21,438	16,272
Current Income Tax Expense (Benefit)	241,725	174,952	119,765
Deferred Federal Income Tax Expense (Benefit)	(864)	(739)	(787)
Deferred State and Local Income Tax Expense (Benefit)	(50,530)	(17,124)	(550)
Increase (Decrease) in Deferred Income Taxes	(190,190)	(103,319)	898
Income Tax Expense (Benefit)	$ 51,535	$ 71,633	$ 120,663
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	(10.80%)	1.40%	2.40%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	(0.10%)	0.90%	0.30%
Effective Tax Rate Reconciliation, Increase (decrease) in Valuation Allowances	(0.10%)	0.20%	(0.10%)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(1.80%)	(0.80%)	(0.50%)
Effective Income Tax Rate Reconciliation, Tax Credits, Foreign	(1.20%)	(1.10%)	(0.30%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	8.60%	12.60%	8.30%
Effective Tax Rate Reconciliation, UK Tax Rate Differential	0%	0%	2.10%
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent	(2.70%)	(5.10%)	(1.90%)
Effective Tax Reconciliation, deferred tax assets and liabilities	0.40%	2.30%	0.40%
U.S. tax reform impact GILTI and FDII	(1.30%)	(0.90%)	(0.60%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent	29%	0%	0%
Capitalized Interest Costs- Effective tax rate	0%	1.80%	0.60%
Effective Income Tax Rate Reconciliation, Other Adjustments	0.30%	(1.00%)	0.10%
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	$ 63	$ 0
Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions	0	(135)
Unrecognized Tax Benefits, Increase Resulting from Acquisition		(746)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation	21	0
Unrecognized Tax Benefits, Decrease Resulting from Acquisition	(503)
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	15,858	14,340
Deferred Tax Assets, Operating Loss Carryforwards	9,407
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	13,150	12,092
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance	2,268	2,561
Deferred Tax Assets, Deferred Income	23,967	20,688
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	3,763	2,187
Deferred Tax Assets, in Process Research and Development	15,382	0
Deferred Tax Assets, Operating leases	46,781	44,401
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	33,559	36,036
Deferred Tax Liabilities, Leasing Arrangements	45,834	43,593
Deferred Tax Assets, Other	11,701	8,579
Deferred Tax Assets, Gross, Current	205,833	168,520
Deferred Tax Assets, Valuation Allowance	20,315	24,691
Deferred Tax Assets, Net of Valuation Allowance	185,518	143,829
Deferred Tax Liabilities, Property, Plant and Equipment	98,601	110,951
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	630,589	755,980
Deferred Tax Liabilities, Pension	2,644	2,004
Deferred Tax and Other Liabilities, Noncurrent	3,186	3,473
Deferred tax liabilities, net of deferred tax assets	780,854	916,001
Deferred Tax Liabilities	(595,336)	(772,172)
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	126,443
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	3,391
Valuation Allowance, Deferred Tax Asset, Change in Amount	(4,376)
Deferred Tax Assets, Operating Loss Carryforwards	37,667	25,550
Undistributed Earnings of Foreign Subsidiaries	1,915,000
IRS settlement paid	7,500
Deferred tax Asset Credit Carryforward, German Branches	26,728
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	157,348	314,503	$ 517,533
Costa Rica Exempt thorugh 2025 and partially exempt through 2029 [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ 2,000
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.02
UNITED STATES
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ (16,759)	79,662	326,991
Current Foreign Tax Expense (Benefit)	138,208	88,158	57,550
Deferred Foreign Income Tax Expense (Benefit)	(114,523)	(73,833)	7,523
Other Foreign Entities [Member]
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	111,443	146,763	117,100
Current Foreign Tax Expense (Benefit)	61,446	53,354	36,699
Deferred Foreign Income Tax Expense (Benefit)	(24,273)	(11,623)	(5,288)
IRELAND
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ 62,664	$ 88,078	$ 73,442

Benefit Plans (Change in benefi

Benefit Plans (Change in benefit obligations funded status) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	$ (159)	$ 153
Defined benefit plan repayment of obligation [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	3,955
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,121
Defined Benefit Plan, Benefit Obligation	7,191	8,525	$ 10,016
Defined Benefit Plan, Service Cost	0	0	0
Defined benefit plan, change in benefit obligation, interest cost	256	232
Defined Benefit Plan, Actuarial Net (Gains) Losses	(807)	(640)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	783	1,083
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(783)	(1,083)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Amount	0	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	783	1,083
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(7,191)	(8,525)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	6,279
Defined Benefit Plan, Benefit Obligation	93,640	129,772	149,200
Defined Benefit Plan, Service Cost	1,276	1,616	1,357
Defined benefit plan, change in benefit obligation, interest cost	3,054	2,820
Defined Benefit Plan, Actuarial Net (Gains) Losses	(27,046)	(12,177)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	5,817	5,375
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	501	897
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(5,772)	(5,325)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(421)	(1,334)
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	501	897
Defined Benefit Plan, Plan Assets, Amount	107,089	142,172	$ 145,452
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	(25,828)	3,421
Defined Benefit Plan, Plan Assets, Contributions by Employer	4,936	5,533
Defined Benefit Plan, Funded (Unfunded) Status of Plan	13,449	12,400
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	(421)	(1,334)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(8,499)	(6,472)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	$ (7,679)	$ (5,875)

Benefit Plans (Amounts recogniz

Benefit Plans (Amounts recognized in balance sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	$ (1,121)	$ (1,190)
Liability, Defined Benefit Plan, Noncurrent	(6,070)	(7,335)
Liability, Defined Benefit Pension Plan	7,191	8,525
Assets for Plan Benefits, Defined Benefit Plan	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	0	0
Liability, Defined Benefit Plan, Noncurrent	(2,876)	(1,772)
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position	13,449
Liability, Defined Benefit Pension Plan		12,400
Assets for Plan Benefits, Defined Benefit Plan	$ 16,325	$ 14,172

Benefit Plans (Amortize pre-tax

Benefit Plans (Amortize pre-tax amount AOCI) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ 750
Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax	$ (5,602)

Benefit Plans (Accumulated bene

Benefit Plans (Accumulated benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Amount	$ 107,089	$ 142,172	$ 145,452
Defined Benefit Plan, Accumulated Benefit Obligation	93,640	129,772
defined benefit plans, aggregate projected benefit obligation	$ 93,640	$ 129,772

Benefit Plans (Projected benefi

Benefit Plans (Projected benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	$ 93,640	$ 129,772	$ 149,200
Defined Benefit Plan, Plan Assets, Amount	107,089	142,172	145,452
Defined Benefit Plan, Accumulated Benefit Obligation	93,640	129,772
Defined Benefit Plan, Service Cost	1,276	1,616	1,357
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	48	61	71
Defined Benefit Plan, Interest Cost	3,054	2,699	2,628
Defined Benefit Plan, Actuarial Net (Gains) Losses	(27,046)	(12,177)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	5,817	5,375
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	501	897
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(7,679)	(5,875)
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	(25,828)	3,421
Defined Benefit Plan, Plan Assets, Contributions by Employer	4,936	5,533
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	501	897
Defined Benefit Plan, Plan Assets, Benefits Paid	5,772	5,325
Defined Benefit Plan, Funded (Unfunded) Status of Plan	13,449	12,400
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	7,191	8,525	10,016
Defined Benefit Plan, Plan Assets, Amount	0	0	0
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	(267)	(3,263)
Defined Benefit Plan, Interest Cost	256	232	$ 317
Defined Benefit Plan, Actuarial Net (Gains) Losses	(807)	(640)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	783	1,083
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	783	1,083
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	783	1,083
Defined Benefit Plan, Funded (Unfunded) Status of Plan	$ (7,191)	$ (8,525)

Benefit Plans (Components of th

Benefit Plans (Components of the annual net periodic benefit cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ 750
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(807)	$ (640)
Defined Benefit Plan, Service Cost	0	0	$ 0
Defined Benefit Plan, Interest Cost	256	232	317
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	(267)	(3,263)
Net amortization and deferral	329	444	439
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	585	409	(2,507)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	0	0	0
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	807	640	114
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	0	267	3,263
Defined Benefit Plan, Amortization of Net Gains (Losses)	(329)	(444)	(439)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	478	463	2,938
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	1,063	872	431
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(27,046)	(12,177)
Defined Benefit Plan, Service Cost	1,276	1,616	1,357
Defined Benefit Plan, Interest Cost	3,054	2,699	2,628
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(3,817)	(4,412)	(3,463)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	48	61	71
Net amortization and deferral	19	18	21
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	531	(49)	614
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	(49)	(31)	0
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	1,716	(11,028)	(1,635)
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	(263)	(222)	(85)
Defined Benefit Plan, Amortization of Net Gains (Losses)	0	0	7
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	1,453	(11,250)	(1,713)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	$ 1,984	$ (11,299)	$ (1,099)

Benefit Plans (Assumptions used

Benefit Plans (Assumptions used in calculating benefit obligations and net periodic benefit cost) (Details)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.70%	2.80%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	3.20%	3.60%	3.50%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.70%	1.80%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.80%	0.90%	1.60%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.05%	0.90%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.95%	1%	0.70%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.80%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.70%	1.50%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.80%	2.85%
Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.75%	3.25%

Benefit Plans (Significant assu

Benefit Plans (Significant assumptions used to determine the net periodic benefit costs) (Details)	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.80%	2.10%	2.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	3.20%	3.60%	3.50%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.80%	0.90%	1.60%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.80%	0.90%	1.60%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.05%	1%	0.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.95%	1%	0.70%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2%	1.50%	1.50%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.20%	2%	1.75%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.80%	2.85%	2.15%
Other Post-Retirement Benefit Plans, Net
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	3.25%	2.50%	3%

Benefit Plans (Assumed long-ter

Benefit Plans (Assumed long-term healthcare cost trend rate) (Details)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Postemployment Benefits [Abstract]
Healthcare cost trend rate medical	7.50%	7%	7%
Healthcare prescription drug	7.50%	7%	7%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.50%	4.50%	4.50%

Benefit Plans (Targeted asset a

Benefit Plans (Targeted asset allocation of plan assets and the actual allocation of plan assets) (Details)	Mar. 31, 2023
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25%

Benefit Plans (Fair value of ou

Benefit Plans (Fair value of our pension benefits plan assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Other Investments	$ 5,387	$ 5,383	$ 5,555
Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	208,357	348,320
Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	5,387	5,383
Trading Securities, Cost	48,137	66,416
Cash and Cash Equivalents, Fair Value Disclosure	338	559
Other Investments	10,285	14,231
Defined Benefit Plan, Plan Assets, Amount	107,089	142,172	$ 145,452
Debt Securities, Trading	42,942	55,583
Other Defined Benefit Pension Plans [Member] | Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	0	0
Cash and Cash Equivalents, Fair Value Disclosure	338	559
Other Investments	0	0
Defined Benefit Plan, Plan Assets, Amount	338	559
Other Defined Benefit Pension Plans [Member] | Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	0	0
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Other Investments	10,285	14,231
Defined Benefit Plan, Plan Assets, Amount	10,285	14,231
Other Defined Benefit Pension Plans [Member] | Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	5,387	5,383
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Other Investments	0	0
Defined Benefit Plan, Plan Assets, Amount	$ 5,387	$ 5,383

Benefit Plans (Expected payment

Benefit Plans (Expected payments to be made to plan participants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Gross Prescription Drug Subsidy Receipts Received (Deprecated 2017-01-31)	$ 477	$ 660
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(27,046)	(12,177)
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	6,279
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	6,265
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	6,458
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	6,663
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	6,845
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	37,315
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	48	61	$ 71
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(807)	(640)
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,121
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	1,019
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	913
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	823
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	731
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	2,620
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ 0	$ (267)	$ (3,263)

Benefit Plans (Details Textual)

Benefit Plans (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 36,564	$ 38,600	$ 29,853
Defined Contribution Plan, Fair Value of Plan Assets	$ 1,170,835
STERIS Corporation shares held in defined contribution plan	483,931
Fair value of STERIS Corporatio stock held in defined contribution plan	$ 92,566
Defined Contribution Plan, Dividends Paid	886	852	$ 839
Deferred Compensation Plan Assets	$ 938	$ 1,061
Equity Securities [Member]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75%
Debt Securities
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25%

Benefit Plans Benefit Plans (Ro

Benefit Plans Benefit Plans (Rollforward of Level 3 assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Other Investments	$ 5,387	$ 5,383	$ 5,555
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Period Increase (Decrease)	(157)	(115)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(159)	153
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3	$ 320	$ (210)

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Loss Contingencies [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	10 years 3 months 18 days	9 years 7 months 6 days
Operating Lease, Payments	$ 45,249	$ 45,144
Fixed Operating Lease Expense	45,249	45,158
Commitments and Contingencies
Letters of credit as security for self insurance risk and retention policies	8,036	13,900
Purchase Commitment, Remaining Minimum Amount Committed	57,221
Variable Operating Lease Expense	21,486	12,659
Operating Lease, Expense	66,735	57,817
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	53,099	$ 79,241
Lessee, Operating Lease, Liability, Payments, Due Year Two	33,584
Lessee, Operating Lease, Liability, Payments, Due Year Three	26,129
Lessee, Operating Lease, Liability, Payments, Due Year Five	19,659
Lessee, Operating Lease, Liability, Payments, Due after Year Five	120,359
Lessee, Operating Lease, Liability, Payments, Due	241,440
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$ 45,986
Operating Lease, Weighted Average Discount Rate, Percent	3.30%	3.40%
Operating Lease, Liability	$ 195,454
Lessee, Operating Lease, Liability, to be Paid, Year One	41,709
Commercial commitments [Member]
Loss Contingencies [Line Items]
Commitments and Contingencies	108,370	$ 98,675
Long term Construction Contracts [Member] [Member]
Loss Contingencies [Line Items]
Commitments and Contingencies	$ 194,505

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022		Mar. 31, 2021	Jun. 02, 2021
Segment Reporting Information [Line Items]
amortization of inventory and property step up to fair value	[1]	$ 12,254	$ 81,804		$ 5,600
amortization and impairment of acquired intangible assets	[1]	376,822	366,434		83,892
Business Combination, Acquisition Related Costs	[2]	24,196	205,788		35,634
loss (gain) on fair value contingent consideration adjustments	[1]	(3,100)	(2,350)		(500)
Gain (Loss) on Disposition of Business	[1]	(67)	(874)		2,030
COVID-19 incremental costs	[3]	0	0		25,793
redomiciliation costs	[4]	661	301		1,592
Restructuring expenses	[5]	485	48		(3,029)
Assets		10,821,839	11,423,594
Payments to Acquire Productive Assets		361,969	287,563		239,262
Depreciation, Depletion and Amortization		552,897	553,104	[6]	219,237
Property, Plant and Equipment, Net		1,705,512	1,552,576
Revenues		4,957,839	4,585,064		3,107,519
Operating Income (Loss)		268,185	425,618		548,368
Contingent Consideration Liability Assumed in Cantel Combination			25,000			$ 25,000
Goodwill, Impairment Loss	[7]	490,565	0		0
Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues		3,085,131	2,845,467		1,954,055
Operating Income (Loss)		706,020	649,704		427,089
Goodwill, Impairment Loss		0
Healthcare and Life Sciences [Member]
Segment Reporting Information [Line Items]
Assets		6,538,270	6,604,893
Payments to Acquire Productive Assets		98,585	84,487		74,446
Depreciation, Depletion and Amortization		306,377	316,222	[6]	106,266
Amortization of Acquired Intangibles and PPE Step Up			229,052
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Assets		3,124,341	3,053,116
Payments to Acquire Productive Assets		253,914	198,350		164,816
Depreciation, Depletion and Amortization		116,153	115,925	[6]	112,971
Revenues		914,431	852,972		685,912
Operating Income (Loss)		429,020	410,101		310,648
Amortization of Acquired Intangibles and PPE Step Up			35,531
Goodwill, Impairment Loss		0
Dental
Segment Reporting Information [Line Items]
Assets		1,159,228	1,765,585
Payments to Acquire Productive Assets		9,470	4,726		0
Depreciation, Depletion and Amortization		130,367	120,957	[6]	0
Revenues		421,573	361,661		0
Operating Income (Loss)		89,527	84,441		0
Amortization of Acquired Intangibles and PPE Step Up			$ 113,099
Goodwill, Impairment Loss		$ 490,565
Dental | Revenue Benchmark | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Percentage		47.40%	45.10%
Historical Average Percentage of Concentration Risk		40%
OperatingSegmentAllExceptCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues		$ 4,957,839	$ 4,585,064		3,107,519
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues		536,704	524,964		467,552
Operating Income (Loss)		210,225	216,188		180,796
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)		(264,791)	(283,665)		(219,153)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Revenues		4,957,839	4,585,064		3,107,519
Operating Income (Loss)		1,170,001	1,076,769		699,380
Adjustments to Liability
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		(3,100)
Additions [Member]
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		8,302	601
Reductions and Payout
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		(80)	(32,336)
Consumable revenues [Member] | Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues		1,050,316	1,004,605		510,946
Consumable revenues [Member] | Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues		241,114	239,365		215,005
Capital equipment revenues [Member] | Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues		896,590	782,505		588,864
Capital equipment revenues [Member] | Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues		26,460	24,394		0
Capital equipment revenues [Member] | Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues		147,420	142,281		128,356
Service revenues [Member] | Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues		1,138,225	1,058,357		854,245
Service revenues [Member] | Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Revenues		887,971	828,578		685,912
Service revenues [Member] | Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues		148,170	143,318		124,191
IRELAND
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		60,570	60,275
Revenues		74,463	82,011		71,905
UNITED STATES
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		946,930	881,057
Revenues		3,586,486	3,228,864		2,227,038
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues		1,296,890	1,274,189		$ 808,576
Other Foreign Entities [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		$ 698,012	$ 611,244
[1]For more information regarding our recent acquisitions and divestitures, refer to Note 2 titled, "Business Acquisitions and Divestitures."[2]Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.[3]COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.[4]Costs incurred in tax restructuring.[5]For more information regarding our restructuring efforts, refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021.[6]Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."[7]For more information regarding our goodwill impairment loss, refer to Note 3 titled, "Goodwill and Intangible Assets."

Common Shares (Details)

Common Shares (Details) - $ / shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Jun. 02, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001			$ 0.001
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Value (EUROS) Ordinary Shares Deferred	25,000
Weighted Average Number of Shares Outstanding, Basic	99,706,000	97,535,000	85,203,000
Weighted Average Number Diluted Shares Outstanding Adjustment	540,000	791,000	695,000
Weighted Average Number of Shares Outstanding, Diluted	100,246,000	98,326,000	85,898,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	578,000	243,000	348,000

Repurchases of Common Shares (D

Repurchases of Common Shares (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($) shares	May 03, 2023 USD ($)	Mar. 31, 2023 EUR (€) shares	Mar. 31, 2023 USD ($) $ / shares shares	Jun. 02, 2021 $ / shares	Jul. 30, 2019 USD ($)	May 07, 2019 USD ($)
Equity, Class of Treasury Stock [Line Items]
Preferred Stock, Shares Authorized					50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares						$ 0.001
Stock Repurchase Program, Authorized Amount | $				$ 500,000		$ 13,932		$ 300,000	$ 78,979
Stock Repurchased During Period, Shares	1,563,983	108,368	35,000
Stock Repurchased and Retired During Period, Value | $	$ 295,000	$ 25,000	$ 5,047
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.001	$ 0.001
Deferred Ordinary Shares					25,000	25,000
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	79,169	244,395	91,567
Payment, Tax Withholding, Share-based Payment Arrangement | $	$ 13,534	$ 30,775	$ 9,599
Euro Member Countries, Euro
Equity, Class of Treasury Stock [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €					€ 1

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	2,794,795
Weighted-average assumptions used for options granted:
Risk-free interest rate	2.44%	1.10%	0.46%
Expected life of options	5 years 10 months 24 days	5 years 10 months 24 days	6 years
Exptected dividend yield of stock	0.80%	0.95%	0.96%
Expected volatility of stock	24.49%	24.27%	23.04%
Estimated forfeiture rate	2.54%	2.85%	2.78%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,560,954
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 138.37
Number of Options, Granted	235,435
Weighted Average Exercise Price, Granted	$ 247.45
Number of Options, Exercised	(37,732)
Weighted Average Exercise Price, Exercised	$ 50.86
Number of Options, Forfeited	(8,928)
Weighted Average Exercise Price, Forfeited	$ 205.25
Number of Options, Outstanding, End of Period	1,749,729	1,560,954
Weighted Average Exercise Price, Outstanding, End of Period	$ 154.60	$ 138.37
Average Remaining Contractual Term, Outstanding	6 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 83,950
Number of Options, Exercisable	1,124,664
Weighted Average Exercise Price, Exercisable	$ 122.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 2 months 12 days
Aggregate Intrinsic Value, Exercisable	$ 79,561
Non-vested stock options outstanding expected to vest	614,758
Common Stock, Fair Market Value Per Share	$ 191.28
Total intrinsic value of stock options exercised	$ 6,502	$ 52,952	$ 39,055
Net cash proceeds from the exercise of stock options	1,828	10,071	26,726
Tax benefit from stock option exercises	$ 4,945	$ 18,143	$ 11,559
Weighted average grant date fair value of stock option grants, per share	$ 50.72	$ 37.52	$ 27.66
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	33,677
Number of Restricted Shares, Granted	13,884
Number of Restricted Shares, Vested	(16,335)
Number of Restricted Shares, Canceled	(2,684)
Number of Restricted Shares, Non-vested at End of Period	28,542	33,677
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 64,814
Weighted average period for recognition of unrecognized compensation cost	2 years 1 month 6 days
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	485,510
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 157.37
Number of Restricted Shares, Granted	131,650
Weighted-Average Grant Date Fair Value, Granted	$ 223.57
Number of Restricted Shares, Vested	(148,828)
Weighted-Average Grant Date Fair Value, Vested	$ 127.98
Number of Restricted Shares, Canceled	(17,539)
Weighted-Average Grant Date Fair Value, Canceled	$ 182.75
Number of Restricted Shares, Non-vested at End of Period	450,793	485,510
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 186.60	$ 157.37
Fair Value, Share-based Payment Awards, Other than Options	$ 21,154
RSUs Cantel
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	45,722
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 191.18
Number of Restricted Shares, Granted	0
Weighted-Average Grant Date Fair Value, Granted	$ 0
Number of Restricted Shares, Vested	(25,470)
Weighted-Average Grant Date Fair Value, Vested	$ 191.18
Number of Restricted Shares, Canceled	(4,582)
Weighted-Average Grant Date Fair Value, Canceled	$ 191.18
Number of Restricted Shares, Non-vested at End of Period	15,670	45,722
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 191.18	$ 191.18
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 1,563
Weighted average period for recognition of unrecognized compensation cost	7 months 6 days
Restricted Stock Units (RSUs)
Summary of share option activity:
Weighted average grant date fair value of stock option grants, per share		$ 191.18
Summary of non-vested restricted share activity:
Share-based Compensation Arrangement by Share-based Payment Award, Conversion Ratio		0.4262
Share-Based Payment Arrangement, Expense		$ 20,200
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value		53,607
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value Attributable to Pre-Acquisition Services		$ 18,173
Weighted Average Number of Shares, Restricted Stock		280,402

Financial and Other Guarantee_2

Financial and Other Guarantees (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Standard and Extended Product Warranty Accrual	$ 13,683	$ 14,108	$ 9,406	$ 7,381
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	13,268	12,571	10,574
Standard Product Warranty Accrual, Decrease for Payments	(13,693)	(12,638)	(8,549)
Standard Product Warranty Accrual, Additions from Business Acquisition	$ 0	$ 4,769	$ 0

Forward and Swap Contracts (Det

Forward and Swap Contracts (Details) $ in Thousands, € in Millions, £ in Millions, $ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2023 USD ($) lb	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2023 GBP (£)	Mar. 31, 2023 MXN ($)	Mar. 31, 2023 SGD ($)	Mar. 31, 2023 EUR (€)	Mar. 31, 2023 USD ($)
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Derivative Assets		$ 2,780						$ 378
Derivative Liabilities		$ 0						$ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration]		Prepaid expenses and other current assets		Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Prepaid expenses and other current assets		Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets	Prepaid expenses and other current assets
Accrued Liabilities
Derivative [Line Items]
Derivative Assets		$ 0						$ 0
Derivative Liabilities		$ 198						$ 2,054
Derivative Liability, Statement of Financial Position [Extensible Enumeration]		Accrued expenses and other		Accrued expenses and other	Accrued expenses and other	Accrued expenses and other	Accrued expenses and other	Accrued expenses and other
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Accrued expenses and other		Accrued expenses and other	Accrued expenses and other	Accrued expenses and other	Accrued expenses and other	Accrued expenses and other
Selling, General and Administrative Expenses
Derivative [Line Items]
Gain (Loss) on Foreign Currency Derivatives Recorded in Earnings, Net	$ 5,036	$ 4,379	$ 1,178
Cost of Sales
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ (3,630)	$ 3,921	$ 771
212230 Copper, Nickel, Lead, and Zinc Mining [Member]
Derivative [Line Items]
Derivative, Nonmonetary Notional Amount, Mass | lb	753,000
Euro Member Countries, Euro | Foreign Exchange Forward
Derivative [Line Items]
Derivative Liabilities | £				£ 19.5
Mexico, Pesos | Foreign Exchange Forward
Derivative [Line Items]
Derivative Asset, Notional Amount					$ 150
Euro Member Countries, Euro | Foreign Exchange Forward
Derivative [Line Items]
Derivative Asset, Notional Amount | €							€ 6
Singapore, Dollars | Foreign Exchange Forward
Derivative [Line Items]
Derivative Asset, Notional Amount						$ 7

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023		Mar. 31, 2022	Mar. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Document Period End Date		Mar. 31, 2023
Equity Securities, FV-NI, Gain (Loss)		$ (1,176)		$ (775)
Business Acquisition, Contingent Consideration, at Fair Value		15,678		10,550	$ 19,642
Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		2,066		2,272
Cash and Cash Equivalents, Fair Value Disclosure		208,357		348,320
Foreign Currency Contract, Asset, Fair Value Disclosure	[1]	0		0
Equity Securities, FV-NI	[2]	7,069		8,520
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	0		0
Deferred Compensation Plan Assets	[2]	1,022		1,240
Long-term Debt, Fair Value	[3]	0		0
Business Acquisition, Contingent Consideration, at Fair Value		0	[4]	0
Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		0		0
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Foreign Currency Contract, Asset, Fair Value Disclosure	[1]	378		2,780
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	2,054		198
Deferred Compensation Plan Assets	[2]	0		0
Long-term Debt, Fair Value	[3]	2,754,218		2,991,680
Business Acquisition, Contingent Consideration, at Fair Value		0	[4]	0
Fair Value, Inputs, Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		0		0
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Foreign Currency Contract, Asset, Fair Value Disclosure		0	[1]	0
Foreign Currency Contracts, Liability, Fair Value Disclosure		0	[1]	0
Deferred Compensation Plan Assets	[2]	0		0
Long-term Debt, Fair Value	[3]	0		0
Business Acquisition, Contingent Consideration, at Fair Value	[4]	15,678		10,550
Additions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		8,302		601
Foreign Currency Gain (Loss)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		6		(7)
Reductions and Payout
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		(80)		(32,336)
Reductions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				(2,350)
Cost of Sales
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain (Loss) on Sale of Commodity Contracts		(3,630)		3,921	$ 771
Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure		2,066		2,272
Cash and Cash Equivalents, Fair Value Disclosure		208,357		348,320
Foreign Currency Contract, Asset, Fair Value Disclosure	[1]	378		2,780
Equity Securities, FV-NI	[2]	7,069		8,520
Foreign Currency Contracts, Liability, Fair Value Disclosure	[1]	2,054		198
Deferred Compensation Plan Assets	[2]	1,022		1,240
Long-term Debt, Fair Value	[3]	3,078,655		3,088,356
Business Acquisition, Contingent Consideration, at Fair Value	[4]	$ 15,678		$ 10,550
[1]The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.[2] We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the Interest income and miscellaneous expense (income) line of the Consolidated Statement of Income. During fiscal 2023 and fiscal 2022, we recorded losses of $(1,176) and $(775), respectively, related to these investments. We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes.

Reclassifications out of AOCI_3

Reclassifications out of AOCI (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (320,710)	$ (209,808)	$ (61,243)	$ (235,463)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		110,437	144,212	(177,548)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(465)	(4,353)	(3,328)
Total other comprehensive (loss) income attributable to shareholders		110,902	148,565	(174,220)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	[1]	12	1,276	(5,519)	(6,813)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(799)	11,148	4,622
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[1]	465	4,353	3,328
Total other comprehensive (loss) income attributable to shareholders	[1]	(1,264)	6,795	1,294
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	[2]	(320,722)	(211,084)	(55,724)	$ (228,650)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[2]	(109,638)	(155,360)	172,926
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	0	0	0
Total other comprehensive (loss) income attributable to shareholders	[2]	$ (109,638)	$ (155,360)	$ 172,926
[1]Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense (income) line of our Consolidated Statements of Income.[2]The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Incom (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (320,710)	$ (209,808)	$ (61,243)	$ (235,463)

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Effect of Fourth Quarter Events [Line Items]
Revenues		$ 4,957,839	$ 4,585,064	$ 3,107,519
Cost of revenues:
Cost of Goods and Services Sold		2,798,147	2,568,702	1,764,419
Gross Profit		2,159,692	2,016,362	1,343,100
Restructuring expenses	[1]	485	48	(3,029)
Net Income (Loss) Attributable to Parent		$ 107,030	$ 243,888	$ 397,400
Earnings Per Share, Basic		$ 1.07	$ 2.50	$ 4.66
Earnings Per Share, Diluted		$ 1.07	$ 2.48	$ 4.63
Service [Member]
Effect of Fourth Quarter Events [Line Items]
Revenues		$ 2,172,512	$ 2,028,783	$ 1,663,979
Cost of revenues:
Cost of Goods and Services Sold		1,284,177	1,148,777	999,343
Product [Member]
Effect of Fourth Quarter Events [Line Items]
Revenues		2,785,327	2,556,281	1,443,540
Cost of revenues:
Cost of Goods and Services Sold		$ 1,513,970	$ 1,419,925	$ 765,076
[1]For more information regarding our restructuring efforts, refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021.

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance		$ 24,691	$ 14,143	$ 13,891
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense		1,733	2,888	2,684
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	[1]	(530)	8,906	277
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction		(5,579)	(1,246)	(2,709)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance		20,315	24,691	14,143
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	[2]	24,371	11,355	12,051
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	[2]	6,972	16,442	3,097
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	[1],[2]	598	1,840	349
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	[2],[3]	(8,514)	(5,266)	(4,142)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	[2]	23,427	24,371	11,355
SEC Schedule, 12-09, Reserve, Inventory
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance		30,937	19,778	16,149
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	[4]	14,313	10,931	4,423
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	[1]	332	228	(794)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction		0	0	0
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance		45,582	30,937	19,778
SEC Schedule, 12-09, Reserve, Casualty Loss
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance		26,126	23,283	23,228
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense		7,829	7,069	5,550
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment		2,040	44	2,542
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction		(5,558)	(4,270)	(8,037)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance		$ 30,437	$ 26,126	$ 23,283
[1]Change in foreign currency exchange rates and acquired reserves.[2]Net allowance for credit losses and allowance for sales and returns.[3]Uncollectible accounts written off, net of recoveries.[4]Provision for excess and obsolete inventory, net of inventory written off.